Semaglutide Clinical Protocol

Table of Contents

1. Indication scope and patient phenotypes
2. Selection criteria (inclusion / exclusion / contraindications)
3. Pre-treatment workup
4. Initiation protocol
5. Maintenance protocol
6. Side-effect management
7. Plateau and non-response algorithm
8. Discontinuation and tapering
9. Combination rules
10. Patient counseling beats
11. Source citations
12. Clinical decision tree

Cross-references

• Canonical:
• Template:
• Voice profile:
• System observations:
• Bibliography (full): (~1,930 PMIDs)

---

1. Indication scope and patient phenotypes

1.1 Purpose

Define where semaglutide applies — the indication scope — and which patient phenotypes within that scope are the protocol’s primary, secondary, and tertiary targets. This section is the applicability gate for every downstream section: selection criteria (§2), workup (§3), initiation (§4), maintenance (§5), AE management (§6), plateau/non-response (§7), discontinuation (§8), combination rules (§9), and counseling beats (§10) all read through the indication scope established here.

does and for whom, anchored in trial-program evidence. Exclusions, contraindications, and regulatory cautions live in §2 and §6 respectively.

1.2 Compound identity and mechanism summary

Semaglutide is a 31-amino-acid synthetic peptide engineered as a long-acting analogue of native GLP-1(7-37), with 94% amino-acid homology to native human GLP-1. Three engineering modifications distinguish it: Ala→AIB at position 8 (DPP-4 resistance), C18 fatty diacid attached to Lys26 via γGlu-2xOEG linker (reversible albumin binding extending half-life to ~165–184 hours / ~7 days), and Lys34→Arg substitution for synthesis specificity. The albumin-binding mechanism enables once-weekly subcutaneous dosing; an SNAC absorption-enhancement formulation enables once-daily oral dosing (Rybelsus). Reference: Lau et al 2015 J Med Chem (PMID 26308095); Knudsen and Lau 2019 Front Endocrinol (PMID 31031702).

Mechanism: GLP-1R agonism across pancreatic β-cells (glucose-dependent insulin secretion), α-cells (glucagon suppression), gastric/intestinal smooth muscle (slowed gastric emptying — both satiety mechanism and dominant GI AE category), hypothalamic POMC/CART (central appetite suppression), hindbrain NTS and vagal afferents (peripheral satiety integration), mesolimbic reward circuits (reduced hedonic intake and food craving — load-bearing for weight-loss magnitude beyond gastric emptying alone), cardiomyocytes/vascular endothelium (anti-inflammatory and BP-reduction mechanisms underlying SELECT outcomes), and kidney proximal tubule (anti-inflammatory and natriuretic effects underlying FLOW outcomes).

1.3 Indication scope — six FDA-approved indications plus one investigational extension

As of 2026-05-13, semaglutide carries the broadest indication scope of any approved GLP-1 RA. This protocol enumerates six FDA-approved indication categories plus one investigational extension under active evaluation.

Indication 1 — Type 2 diabetes mellitus, glycemic control (Ozempic 2017 SC; Rybelsus 2019 oral). FDA label: as adjunct to diet and exercise to improve glycemic control in adults with T2D. Pivotal program: SUSTAIN-1 through SUSTAIN-10 (injectable); PIONEER-1 through PIONEER-10 (oral). Primary endpoint: HbA1c change from baseline. Effect-size anchors: SUSTAIN-7 head-to-head vs dulaglutide demonstrated semaglutide 1.0 mg HbA1c reduction approximately 1.8 percentage points at 40 weeks (Pratley 2018, PMID 29397376); PIONEER PLUS oral 25/50 mg demonstrated superiority over 14 mg (Aroda 2023, PMID 37385279). SUSTAIN-FORTE 2.0 mg label expansion provides incremental HbA1c reduction at the cost of additional GI AE. Phenotype primary target: T2D adults with HbA1c 7.0–10.0%, metformin-treated or metformin-intolerant.

Indication 2 — Chronic weight management, adults (Wegovy 2.4 mg, FDA-approved 2021; Wegovy HD 7.2 mg, FDA-approved March 19, 2026 via Commissioner’s National Priority Voucher Program; oral Wegovy 25 mg, FDA-approved August 2025). FDA label: as adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with initial BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, ASCVD). Pivotal program: STEP-1 through STEP-8 plus STEP UP / Wegovy HD plus OASIS oral program. Primary endpoint: percent change in body weight from baseline at week 68. Effect-size anchors:

• STEP-1 (Wilding 2021 NEJM, PMID 33567185; n=1,961 non-diabetic obesity BMI ≥30): –14.9% body weight vs –2.4% placebo at 68 weeks
• STEP-2 (Davies 2021 Lancet, PMID 33667417; T2D + obesity): –9.6% vs –3.4% — smaller effect size in T2D phenotype
• STEP-3 (Wadden 2021 JAMA, PMID 33625476; intensive behavioral therapy adjunct): –16.0% vs –5.7% with IBT plus placebo — IBT is effect-additive
• STEP-4 (Rubino 2021 JAMA, PMID 33755728; withdrawal study): load-bearing for discontinuation framing in §8
• STEP-5 (Garvey 2022 Nat Med, PMID 36216945; two-year long-term)
• STEP-8 (Rubino 2022 JAMA, PMID 35015037; vs liraglutide head-to-head): –15.8% vs –6.4% — semaglutide ~2.5-fold greater weight reduction than liraglutide
• STEP UP / Wegovy HD (Wharton 2025 Lancet Diabetes Endocrinol, PMID 40961952; semaglutide 7.2 mg): –18.7% body weight; 31.2% achieving ≥25% loss — supporting March 2026 Wegovy HD approval
• OASIS 4 (Wharton 2025 NEJM, PMID 40934115; oral 25 mg for obesity): –13.6% treatment-policy / –16.6% adherent — supporting August 2025 oral Wegovy approval

Indication 3 — Chronic weight management in adolescents ≥12 years (Wegovy adolescent label, FDA-approved 2022). FDA label: BMI at the 95th percentile or greater. Pivotal trial: STEP TEENS (Weghuber 2022 NEJM, PMID 36322838; NCT04102189). Primary endpoint: percent BMI change at 68 weeks. Effect-size anchor: –16.1% BMI with semaglutide 2.4 mg vs +0.6% placebo. Phenotype primary target: pediatric/adolescent obesity. Use within structured lifestyle-intervention framework and pediatric obesity-medicine specialist oversight where available. Long-term developmental, reproductive, and psychosocial outcomes surveillance is ongoing.

Indication 4 — Cardiovascular risk reduction (Ozempic 2020 for T2D + established CVD; Wegovy expansion March 8, 2024 for BMI ≥27 + established CVD without diabetes; Rybelsus oral 2025 for T2D + ASCVD/CKD). FDA label: to reduce the risk of MACE. Pivotal trials and effect-size anchors:

• SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186; n=3,297 T2D + established CVD): HR 0.74 for three-point MACE composite (26% relative reduction) at median 2.1 years
• SELECT (Lincoff 2023 NEJM, PMID 37952131; n=17,604 BMI ≥27 + established CVD without diabetes): HR 0.80 for three-point MACE (20% relative reduction) over mean 39.8 months; 4-year durability data (Ryan 2024 Nat Med, PMID 38740993): –10.2% mean weight loss maintained at 208 weeks
• SOUL (McGuire 2025 NEJM, PMID 40162642; oral semaglutide 14 mg in T2D + ASCVD/CKD; n=9,650): 14% MACE reduction — first CV outcomes trial confirming benefit for an oral GLP-1 agent

Phenotype primary target: secondary-prevention adults with documented ASCVD.

Indication 5 — Metabolic dysfunction-associated steatohepatitis (Wegovy MASH expansion, FDA-approved August 15, 2025). FDA label: for the treatment of adults with MASH with moderate-to-advanced fibrosis (F2–F3). Pivotal trial: ESSENCE (Sanyal/Newsome 2025 NEJM, PMID 40305708; NCT04822181; n=800 biopsy-proven MASH F2/F3 at 72 weeks). Both co-primary endpoints met: 62.9% MASH resolution without worsening fibrosis (vs 34.3% placebo) and 36.8% fibrosis improvement without worsening of steatohepatitis (vs 22.4%). Phenotype primary target: biopsy- or imaging-confirmed MASH with F2–F3 fibrosis. F4 cirrhosis caveat: Loomba 2023 Phase 2 in F4 cirrhosis (n=71; PMID 36934740) reported fibrosis improvement 11% semaglutide vs 29% placebo (p=0.087, NS but directionally toward placebo advantage). ESSENCE approval is F2/F3 only; F4 evidence does not support semaglutide for fibrosis improvement and the directional finding warrants caution in off-label F4 use.

Indication 6 — Chronic kidney disease in T2D (Ozempic FLOW expansion, FDA-approved 2025). FDA label: to reduce the risk of sustained eGFR decline ≥50%, kidney failure, kidney death, or CV death in adults with T2D and CKD. Pivotal trial: FLOW (Perkovic 2024 NEJM, PMID 38785209; NCT03819153; n=3,533 T2D + CKD at median 3.4 years). Effect-size anchors: 24% relative reduction in primary kidney composite outcome; 18% lower MACE; 20% lower all-cause mortality. Trial stopped early at planned interim analysis for efficacy. Phenotype primary target: T2D adults with eGFR 25–75 and UACR 100–5000, on maximally tolerated renin-angiotensin system blockade.

Investigational extension — HFpEF with obesity. STEP-HFpEF (Kosiborod 2023 NEJM, PMID 37622681; KCCQ-CSS +16.6 vs +8.7), STEP-HFpEF-DM (Kosiborod 2024 NEJM, PMID 38587233, with T2D), and pooled STEP-HFpEF (Butler 2024 Lancet, PMID 38599221, n=1,145) demonstrated KCCQ-CSS improvement, 6MWT, and weight loss in obesity-related HFpEF. The 4-trial pooled HF analysis (Kosiborod 2024 Lancet, PMID 39222642; n=3,743 with HF across SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM): HR 0.69 for CV death or worsening HF events. As of 2026-05-13, this is supportive Phase 3 data; label expansion is pending. do not state “FDA-approved for HFpEF” — state “supportive Phase 3 data from STEP-HFpEF / STEP-HFpEF-DM; label expansion not granted as of 2026-05-13.”

Additional active research directions: peripheral artery disease (STRIDE Bonaca 2025 Lancet, PMID 40169145; n=792 T2D + symptomatic PAD; first trial demonstrating walking-capacity and quality-of-life improvement); polycystic ovary syndrome (Chen 2025 RCT, PMID 40713699); addiction biology (alcohol use Hendershot 2025, PMID 39937469; tobacco Wang 2024, PMID 39074369); sleep apnea (weight-loss-mediated). Alzheimer’s disease — important null finding: evoke and evoke+ Phase 3 primary endpoint (CDR-SB) NOT met (Johannsen 2026 Lancet, DOI 10.1016/S0140-6736(26)00459-9; n=3,808 early AD; 104 weeks). AD is not currently an evidence-supported indication for semaglutide.

1.4 Phenotype-targeting taxonomy

Within each indication category, phenotype targeting refines selection per the §1.3 (Template) phenotype dimensions. For semaglutide, the trial-program phenotypes most heavily populated:

• Metabolic phenotype. Insulin-resistant obesity (STEP program, SURMOUNT class context); T2D with retained β-cell function.
• Adiposity distribution. Visceral-dominant obesity; android pattern. Ectopic-fat-positive (hepatic steatosis, pancreatic steatosis, epicardial fat) — the MASH-relevant phenotype anchored to ESSENCE.
• Appetite phenotype. Hyperphagia-dominant and hedonic-eating-dominant phenotypes match the central appetite-suppression and reward-circuit mechanisms most strongly. Slow-satiety-dominant phenotype benefits from gastric-emptying-delay mechanism. Nocturnal-eating phenotype response is less characterized.
• Energy-expenditure phenotype. Adaptive-thermogenesis-prone (post-prior-weight-loss patients with regain) is the typical STEP-1 enrollment phenotype.
• Comorbidity load. Polycondition phenotype (T2D + MASH + CKD + ASCVD) is qualitatively different from monocondition phenotype for combination-rule purposes (§9). The polycondition phenotype is well-represented across the semaglutide trial program (SUSTAIN, SELECT, FLOW, ESSENCE overlap).
• Pharmacologic history. Prior GLP-1 RA exposure (response/non-response/intolerance) — STEP-8 head-to-head positions semaglutide as ~2.5× liraglutide on weight-loss magnitude (PMID 35015037). Prior bariatric surgery with weight regain — under-represented in registration trials but a clinically common scenario.
• Life-stage modifier. Reproductive-age female (pregnancy planning is a §8 discontinuation trigger — see Anchor 3 in §10). Adolescent ≥12 (STEP TEENS, separate label). Older adult (≥65) — generally enrolled across program but lean-mass concern in §3.8 baseline applies. Pediatric <12 — not enrolled in registration program; monogenic obesity pediatric expansion under investigation (NCT07302802).

A semaglutide protocol identifies which phenotype dimensions are primary targets (trial-enrolled phenotype the molecule was developed for), secondary targets (phenotypes with supporting evidence outside the registration trials — e.g., HFpEF + obesity per STEP-HFpEF; PAD per STRIDE), and tertiary / off-target.

1.5 Indication-by-formulation operational map

Semaglutide is available in three branded formulations plus one approved oral platform plus a compounded-pharmacy real-world clinical option (§8.7). The protocol selects formulation by indication:

Indication	Approved formulation	Approved dose	Pivotal anchor
T2D glycemic control	Ozempic SC; Rybelsus oral	Ozempic 0.5–2.0 mg weekly; Rybelsus 7–25 mg daily	SUSTAIN program; PIONEER program
T2D + ASCVD/CKD CV risk reduction (oral)	Rybelsus oral	14 mg daily	SOUL (PMID 40162642)
T2D + CVD MACE reduction (SC)	Ozempic SC	1.0 mg weekly (SUSTAIN-6 dose)	SUSTAIN-6 (PMID 27633186)
T2D + CKD kidney composite	Ozempic SC	1.0 mg weekly (FLOW dose)	FLOW (PMID 38785209)
T2D + PAD walking capacity	Ozempic SC	1.0 mg weekly	STRIDE (PMID 40169145)
Chronic weight management, adults	Wegovy SC; oral Wegovy 25 mg	Wegovy 2.4 mg weekly; oral Wegovy 25 mg daily	STEP program; OASIS 4
Chronic weight management, higher-dose	Wegovy HD SC	7.2 mg weekly (post-tolerance escalation)	STEP UP (PMID 40961952)
Adolescent obesity (≥12 years)	Wegovy SC	Adult titration 0.25 → 2.4 mg weekly	STEP TEENS (PMID 36322838)
CV risk reduction, non-diabetic BMI ≥27 + CVD	Wegovy SC	2.4 mg weekly	SELECT (PMID 37952131)
MASH F2/F3	Wegovy SC	2.4 mg weekly	ESSENCE (PMID 40305708)
HFpEF + obesity (investigational; label expansion pending)	Wegovy SC off-label	2.4 mg weekly	STEP-HFpEF program

Each row above carries a specific FDA-approved-indication framing OR an explicit investigational / off-label framing. Where the framing is investigational (“HFpEF + obesity” row), the language does not state “FDA-approved” — it states “label expansion pending” and the clinical use is clinician-judgment within informed-consent and primary-source-supported clinical reasoning.

1.6 Comparator-class positioning

Semaglutide operates within the GLP-1 RA / GLP-1 RA-anchored combination landscape. The dominant comparator classes:

• Within-class single agonists — liraglutide (STEP-8 head-to-head, semaglutide ~2.5× greater weight reduction); dulaglutide (SUSTAIN-7 head-to-head, semaglutide superior on HbA1c and weight); exenatide (largely superseded).
• GLP-1/GIP coagonists — tirzepatide. SURMOUNT-5 direct head-to-head (Aronne 2025 NEJM, PMID 40353578; n=751 obesity without T2D; max-tolerated-dose comparison at week 72): tirzepatide –20.2% vs semaglutide –13.7% — ~6.5 percentage-point difference favoring tirzepatide; P<0.001.no head-to-head Wegovy 7.2 mg vs Zepbound 15 mg trial exists as of 2026-05-13. Class-differentiation: NAION signal documented for semaglutide; signal absent for tirzepatide at same threshold per Lakhani 2025 PMID 40383360. Verbatim Anchor 4 in §10.
• GLP-1/GIP/glucagon triagonists — retatrutide. TRIUMPH-4 Phase 3 topline readout December 11, 2025 (NCT05931367; n=445; 68 weeks obesity + knee OA): –28.7% body weight at 12 mg per Lilly investor disclosure; peer-reviewed publication pending as of 2026-05-13. Not yet FDA-approved.
• GLP-1/glucagon dual agonists — survodutide. SYNCHRONIZE-1 obesity Phase 3 April 2026 readout: 16.6% weight loss vs placebo. FDA Breakthrough Therapy designation for MASH. Not yet approved.
• Oral non-peptide small-molecule GLP-1R agonists. Orforglipron (Eli Lilly LY3502970): ACHIEVE-1 T2D Phase 3 (PMID 40544435) HbA1c absolute reduction –1.24% to –1.48%; ATTAIN-1 obesity Phase 3 (PMID 40960239) meaningful weight loss. Regulatory submission anticipated 2025–2026. Aleniglipron (Structure Therapeutics): ACCESS II Phase 2 16.3% placebo-adjusted weight loss at 180 mg / 44 weeks (March 2026 readout); not yet Phase 3./Small-Molecules/, not /Peptides/.
• Combo products — CagriSema. REDEFINE-1 Phase 3 (PMID 40544433; Garvey et al; n=3,417 obesity without T2D; 68 weeks): –20.4% body weight (treatment-policy estimand) vs –3.0% placebo; 22.7% at full adherence vs 16.1% semaglutide alone, 11.8% cagrilintide alone. REDEFINE-2 in T2D (PMID 40544432): –13.7% body weight vs –3.4% placebo. Combination class — see §9.
• MariTide (bispecific anti-GIPR antibody + GLP-1R peptide). Mechanism distinct: GIPR antagonism + GLP-1R agonism. Phase 3 MARITIME program active; phase 2 weight-loss magnitude in line with high-dose Wegovy and tirzepatide range.

1.7 Compounded semaglutide context

Compounded semaglutide is a real-world clinical option used by a substantial patient population. It emerged during the 2022–2024 FDA-declared shortage periods through two regulatory pathways:

• 503A pathway — state-licensed pharmacies compounding to individual prescriptions; oversight via state boards of pharmacy
• 503B pathway — FDA-registered outsourcing facilities compounding for office-stock and patient prescriptions; oversight via FDA cGMP inspection

Persists as clinical reality as of 2026-05-13 per the FDA’s February 2025 declaration that the semaglutide shortage was resolved (post-shortage status varies by formulation; clinicians should verify current FDA shortage list). Section 8.7 of this protocol and verbatim §10 Anchors 1 + 2 develop the operational characteristics and counseling beats.

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who semaglutide is for, who it is not for, and who it must not be given to. §2 operationalizes the indication scope from §1 into actionable clinical screening criteria. Reversing that ordering would steer clinicians away from the compound before they have read the inclusion case.

FDA boxed warning, labeled contraindication, labeled precaution / cautionary use, or post-marketing pharmacovigilance signal under evaluation. The distinctions matter operationally: a boxed-warning contraindication is absolute and immediate-discontinuation if discovered during therapy; a labeled precaution is clinician-judgment with informed consent.

2.2 Inclusion criteria — the trial-enrolled and label-permitted phenotype

Inclusion is stated as the population the pivotal trial program enrolled and the FDA label permits. By indication:

T2D glycemic control (Ozempic / Rybelsus). Adults age ≥18; HbA1c 7.0–10.0% (typical SUSTAIN / PIONEER enrollment range; FDA label does not stipulate ceiling); adjunct to diet and exercise; metformin-treated or metformin-intolerant. Rybelsus-specific inclusion considerations: patient capable and willing to adhere to SNAC-absorption discipline — empty stomach upon waking, ≤120 mL water, 30-minute pre-food window. Patients on proton-pump inhibitors require PPI-absorption interaction counseling per PIONEER program findings.

T2D + ASCVD / CKD CV risk reduction (Rybelsus oral 14 mg). Adults with T2D and established ASCVD or CKD per SOUL enrollment (PMID 40162642).

T2D + CVD MACE reduction (Ozempic 1.0 mg). Adults with T2D and established CVD per SUSTAIN-6 enrollment (PMID 27633186).

T2D + CKD kidney composite (Ozempic 1.0 mg). Adults with T2D, eGFR 25–75, UACR 100–5000, on maximally tolerated RAS blockade per FLOW enrollment (PMID 38785209). RAS-blockade documentation at maximally tolerated dose is the FLOW protocol-equivalent background-therapy requirement.

T2D + symptomatic PAD walking capacity (Ozempic 1.0 mg). Adults with T2D and Fontaine IIa symptomatic PAD per STRIDE enrollment (PMID 40169145).

Chronic weight management, adults (Wegovy SC; oral Wegovy 25 mg). Adults age ≥18 with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, ASCVD).

Higher-dose chronic weight management (Wegovy HD 7.2 mg). Adults who have tolerated Wegovy 2.4 mg for ≥4 weeks and have not reached weight-loss goal — STEP UP enrollment / FDA label criteria (PMID 40961952).

Adolescent obesity (Wegovy 2.4 mg SC, ≥12 years). Adolescents aged 12 and older with BMI at the 95th percentile or greater per STEP TEENS enrollment (PMID 36322838).

CV risk reduction, non-diabetic obesity + established CVD (Wegovy 2.4 mg). Adults with BMI ≥27 and established CVD without diabetes per SELECT enrollment (PMID 37952131).

MASH F2/F3 (Wegovy 2.4 mg). Adults with biopsy- or imaging-confirmed MASH and moderate-to-advanced fibrosis (F2–F3) per ESSENCE enrollment (PMID 40305708). Hepatology co-management for F3 fibrosis or above is the protocol-recommended practice (§3.4).

Cross-cutting inclusion considerations (all indications):

• Pregnancy / lactation status: not currently pregnant; on contraception if reproductive-age (§8 discontinuation-trigger arithmetic).
• Capability to self-administer subcutaneous injection (for injectable formulations) or adhere to oral-formulation absorption discipline (Rybelsus).
• Engagement with diet and exercise / lifestyle intervention (label-required adjunct framing for CWM indications; STEP-3 demonstrated IBT effect-additivity per PMID 33625476).

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where semaglutide is not contraindicated but where benefit is uncertain, risk is elevated, or trial data are sparse. Structure per relative exclusion: state the criterion; underlying concern; magnitude of trial evidence; recommended clinician-judgment posture.

Severe gastroparesis or gastroparesis-predisposing comorbidity. GLP-1 RA mechanism includes delayed gastric emptying; in established gastroparesis, anatomical and symptomatic worsening risk is elevated. Trial programs typically excluded severe gastroparesis. Clinician-judgment posture: not initiated in severe gastroparesis; clinician-judgment in mild gastroparesis with shared decision-making.

Active or recent (within 12 months) acute pancreatitis. Distinct from prior severe pancreatitis history (a §2.4 cautionary use / precaution per current label) — recent acute pancreatitis is a relative exclusion with clinician-judgment posture. Pivotal trials (SUSTAIN, STEP, SELECT, FLOW, ESSENCE) have not demonstrated a statistically significant pancreatitis-incidence signal beyond placebo, but Wen 2025 systematic review (PMID 40988099; 62 RCTs, n=66,232) shows pooled RR 1.44 (95% CI 1.09–1.89, p=0.009) for acute pancreatitis — modest signal, authors frame as “slightly increased risk, likely minimal.” Absolute event rates remain low (<1–2% per year). Posture: defer until at least 12 months stable post-event with clinician judgment thereafter.

Severe gastrointestinal disease (active IBD flare, severe GERD with esophagitis). GLP-1 RA GI AE profile may exacerbate. Relative — clinician judgment.

Diabetic retinopathy with recent rapid HbA1c improvement risk. SUSTAIN-6 documented a retinopathy-complication signal in patients with rapid glycemic improvement. the signal is anchored to the rapid-improvement sub-population — not generalized to all semaglutide patients. Posture: ophthalmology pre-screening for proliferative diabetic retinopathy or advanced background DR; gradual titration to mitigate rapid glycemic improvement; co-management with ophthalmology.

NAION risk factors (semaglutide-specific signal under evaluation). Crowded optic disc (small or “disc-at-risk” anatomy), prior NAION in fellow eye, hypertension, sleep apnea, dyslipidemia. NAION is EMA-labeled as “very rare” per EMA PRAC June 2025 (~1 case per 10,000 person-years; ~two-fold increase vs non-users); FDA has not updated US labels as of 2026-05-13 — US/EU labeling divergence. Multiple converging lines of evidence (Hathaway 2024 PMID 38958939; Grauslund Danish nationwide PMID 39696569; Lakhani 180-country pharmacovigilance PMID 40383360; Cheng 2026 PMID 41021211). Class-differentiation: no significant NAION signal for tirzepatide at the same threshold per PMID 40383360. Posture: counsel patients regardless of FDA label status; ophthalmology pre-screen if disc-at-risk anatomy, prior NAION, or unexplained visual symptoms.

Severe renal impairment outside trial-enrolled range. For CKD-indication use (FLOW), trial enrollment was eGFR 25–75; eGFR 15–25 is a relative exclusion with clinician-judgment posture and nephrology co-management; eGFR <15 is outside any Phase 3 enrollment and direction-of-effect is not established.

Severe hepatic impairment (Child-Pugh C) outside trial-enrolled range. ESSENCE excluded F4 cirrhosis; Loomba 2023 Phase 2 in F4 (n=71, PMID 36934740) reported directionally toward placebo advantage on fibrosis improvement (11% vs 29%, p=0.087 NS). Posture: not used for MASH indication in F4; clinician judgment for other indications in Child-Pugh C with hepatology co-management.

Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging). The appetite-suppression mechanism is contraindicated in disordered eating; ARFID and BED-without-purging are clinician-judgment phenotypes routed to behavioral-health co-management before initiation.

Active malignancy on therapy (other than MTC / MEN-2 contraindication — see §2.4). Trial programs typically excluded active cancer; clinician judgment with oncology co-management. the 2026 definitive cancer SR (Ko et al Annals Intern Med 2026, PMID 41359966; n=94,245 across 48 RCTs) characterizes GLP-1 RA effects on 11 cancer types + multiple myeloma + meningioma as moderate-certainty “little or no effect” (thyroid, pancreatic, breast, kidney) or low-certainty “may have little or no effect” (colorectal, esophageal, liver, gallbladder, ovarian, endometrial, multiple myeloma, meningioma). Active malignancy is the operational concern, not the cancer-incidence signal.

Severe psychiatric disease with suicidality risk. Note: the suicidal-ideation warning was removed from the FDA label in 2025 and from the EMA label in 2024–2025 following review. Bezin 2024 EClinicalMedicine (PMID 39844933) French nationwide case-time-control found OR 0.62 (95% CI 0.51–0.75) — no signal of harm. Standard depression / suicidality screening per age-appropriate practice continues. Posture: not a relative exclusion based on suicidality risk alone; clinician judgment with mental-health co-management for active severe psychiatric disease.

2.4 Hard contraindications — boxed warnings and labeled contraindications

Hard contraindications are absolute — semaglutide must not be initiated, and if discovered during therapy, semaglutide is discontinued.

Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for GLP-1 RAs including semaglutide, based on rodent C-cell tumorigenicity signal (Bjerre Knudsen 2010, PMID 20203154). the rodent C-cell signal is species-specific and does not translate to primates; human C-cells express GLP-1R at much lower density than rodent C-cells. The 2026 cancer SR (PMID 41359966) characterizes thyroid cancer signal as moderate-certainty “little or no effect” overall. Regulatory framing remains absolute despite mechanism-and-epidemiology nuance: the boxed warning is the operational standard.

Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same FDA boxed warning. Absolute contraindication.

Known serious hypersensitivity to semaglutide or excipient. Labeled contraindication. Includes anaphylaxis and angioedema history.

Severe prior pancreatitis history (severe acute or chronic). Labeled cautionary use / precaution (not labeled-as-absolute-contraindication per current label; protocol documents current label language at each iteration). The Wen 2025 SR signal (PMID 40988099) supports the cautionary framing; clinical practice often treats severe pancreatitis history as effectively excluding semaglutide initiation unless alternatives are exhausted and informed consent documents the residual risk.

Pregnancy (for chronic weight management and most metabolic indications). Labeled contraindication for CWM indications (Wegovy) per current label. Pregnancy is a §8 discontinuation trigger — a patient on protocol who becomes pregnant transitions out of protocol immediately with immediate discontinuation and obstetrics co-management. The verbatim Anchor 3 framing in §10 leads with research-state Parker 2025 data before regulatory framing.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before semaglutide initiation. §3 is the operational handoff between §2 (selection criteria) and §4 (initiation protocol): a patient who passes §2 screening enters §3 workup; only on workup completion does §4 dose initiation begin.

The semaglutide workup is structured into seven panels per the Module 5 framework: standard metabolic (every patient), diabetes-specific (T2D indication or T2D comorbidity), MASH-specific (MASH indication or MASH risk profile), kidney-specific (CKD indication or borderline baseline kidney function), CV-risk-specific (CVOT indication or ASCVD risk profile), organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs plus semaglutide-specific NAION pre-screen), and body-composition baseline (every CWM patient).

Every lab listed in §3.2–§3.8 is reconciled with §5 maintenance monitoring intervals (§5 cannot recommend a monitoring lab not established as a baseline lab in §3) and with §6 AE management triggers.

3.2 Standard metabolic panel

Applies to every semaglutide patient regardless of indication.

Test	CPT	Rationale	Medicare allowable	DTC self-pay range
Hemoglobin A1c	83036	Glycemic baseline; T2D diagnostic confirmation; rapid-improvement-mediated retinopathy risk identification (§6.7)	$9.71	29–39
Fasting blood glucose	82947	Glycemic baseline; complement to HbA1c	$3.93	$28
Comprehensive metabolic panel	80053	Renal/hepatic/electrolyte baseline; includes glucose, creatinine, eGFR, AST, ALT	$10.56	29–49
Lipid panel	80061	Cardiovascular baseline; SELECT-trial-relevant risk stratification	$13.39	29–59
TSH	84443	Thyroid screen; MTC contraindication context (§3.7)	$16.80	35–49

Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor (§1.4 phenotype taxonomy) and a load-bearing marker for MASH-risk screening (§3.4).

Blood pressure (seated, two readings, standardized). Baseline for CV-risk indication eligibility and for monitoring. GLP-1 RA SBP reduction is a documented secondary effect; baseline BP context shapes hypertension co-medication adjustment.

Baseline panel cost summary: Medicare allowable 54.39; DTCself − pay(cheapestsingle − source) 144. The 2–7× DTC/Medicare ratio is the operative cost-conscious decision context for self-pay patients.

Frequency: baseline panel obtained within 4–12 weeks before semaglutide initiation; sooner if recent exam not available.

3.3 Diabetes-specific panel (T2D indication or T2D comorbidity)

Applies when the indication is T2D glycemic control, T2D + CV risk, T2D + CKD, T2D + PAD, or when T2D is a comorbidity within a CWM / CV / MASH indication.

• HbA1c (above; standard panel) — confirms T2D diagnosis and severity.
• Fasting C-peptide. Establishes endogenous insulin reserve; distinguishes T2D from LADA and from advanced beta-cell-failure T2D where GLP-1 RA monotherapy response may be attenuated.
• GAD-65 antibodies and IA-2 antibodies (if LADA suspected). Adult-onset diabetes with normal BMI, rapid progression to insulin requirement, or atypical course. GLP-1 RAs are not first-line in confirmed autoimmune diabetes; misclassification risks the assumed benefit not applying.
• Diabetes complication screen (if not within the last 12 months): dilated retinal exam (also class-wide pre-treatment requirement per §3.7); urine albumin-to-creatinine ratio (UACR) for diabetic nephropathy; monofilament / vibratory testing for diabetic neuropathy.
• Microalbumin / creatinine ratio (CPT 82570). Medicare $5.18; DTC 45–49. Preferred over microalbumin alone for sensitivity; complement to eGFR from CMP. Required for FLOW-equivalent CKD-indication eligibility.
• CGM data review if available. Establishes time-in-range baseline and hypoglycemia frequency baseline. Relevant for §5 dose-adjustment triggers in patients on concurrent insulin or sulfonylurea.

Retinal exam urgency anchored to HbA1c. HbA1c ≥9.0 → pre-treatment dilated exam required before initiation; HbA1c <9.0 → exam within 6–12 months. SUSTAIN-6 (PMID 27633186) documented a retinopathy-complication signal in patients with rapid-HbA1c-improvement sub-population; this anchors the urgency framework.

3.4 MASH-specific panel (MASH indication or MASH risk profile)

Applies when the indication is MASH or when baseline phenotype suggests MASH risk (T2D + obesity + elevated AST/ALT on standard panel + waist circumference ≥102 cm men / ≥88 cm women).

• AST, ALT, GGT, alkaline phosphatase, total and direct bilirubin (CMP plus GGT). Hepatic-function baseline.
• Platelet count (CBC). Component of FIB-4 calculation.
• FIB-4 score. Calculated non-invasive fibrosis score (age × AST / [platelets × √ALT]). Stratifies fibrosis risk: low <1.3, indeterminate 1.3–2.67, high >2.67.
• Vibration-controlled transient elastography (VCTE / FibroScan) if FIB-4 indeterminate or high. Liver stiffness measurement (kPa) plus controlled-attenuation parameter (CAP) for steatosis quantification. Stratification: low <8 kPa, indeterminate 8–12 kPa, high >12 kPa for advanced fibrosis.
• Liver biopsy is the historical gold standard for MASH diagnosis and fibrosis staging but is invasive; for ESSENCE-anchored MASH indication eligibility (PMID 40305708), biopsy- or imaging-confirmed MASH is acceptable. Modern practice favors non-invasive elastography unless biopsy is clinically indicated for staging or to rule out alternative liver disease.
• Hepatitis B surface antigen and Hepatitis C antibody. Rule out viral hepatitis as alternative or co-existing liver disease.
• Iron studies (ferritin, transferrin saturation). Rule out hereditary hemochromatosis; elevated ferritin is common in MASH but very high transferrin saturation suggests iron-overload alternative.
• Autoimmune liver-disease screen if clinically indicated (ANA, anti-smooth muscle, anti-mitochondrial antibodies).

F4 cirrhosis exclusion. ESSENCE excluded F4 cirrhosis; Loomba 2023 Phase 2 in F4 (n=71, PMID 36934740) reported fibrosis improvement 11% semaglutide vs 29% placebo (p=0.087, NS but directionally toward placebo advantage). F4 patients are out of MASH-indication scope; clinician judgment with hepatology co-management for other indications.

Hepatology co-management. Required for F3 fibrosis or above; recommended for indeterminate-or-high FIB-4 pending elastography clarification.

3.5 Kidney-specific panel (CKD indication or borderline baseline kidney function)

Applies when the indication is CKD-in-T2D (FLOW-anchored Ozempic 1.0 mg) or when baseline eGFR is 30–60 regardless of indication.

• Serum creatinine, eGFR (CMP component).
• Cystatin C-based eGFR if creatinine-eGFR is discordant with clinical picture (e.g., low muscle mass elderly patient with apparently normal creatinine but real GFR reduction).
• Urine albumin-to-creatinine ratio (UACR). Quantifies albuminuria — FLOW enrollment criterion was UACR 100–5000; protocol documents UACR for any patient where CKD is an indication or risk.
• Urinalysis with microscopy. Rules out alternative kidney disease (active sediment, hematuria, proteinuria pattern).
• Renin-angiotensin system (RAS) blockade documentation. FLOW enrollment required maximally tolerated RAS blockade as background therapy; this is the FLOW-equivalent background-therapy requirement for the CKD-indication semaglutide protocol.
• Serum bicarbonate, phosphorus, calcium, PTH if eGFR <60. Chronic-kidney-disease-mineral-and-bone-disorder workup; relevant for advanced CKD co-management.
• Potassium (CMP). Relevant for CKD context and for concurrent RAS-blockade dose-titration safety.

Outside-FLOW-range posture. eGFR 15–25: relative exclusion; nephrology co-management; clinician judgment. eGFR <15: outside any Phase 3 enrollment and direction-of-effect not established.

3.6 CV-risk-specific panel (CVOT indication or ASCVD risk profile)

Applies when the indication is CV risk reduction (SUSTAIN-6 / SELECT / SOUL-anchored) or when baseline ASCVD risk profile is high regardless of indication.

• ECG (12-lead). Baseline rhythm and conduction status; relevant for QT considerations in concurrent medications and for AF screening in obesity-related cardiomyopathy.
• High-sensitivity troponin if symptomatic baseline. Rules out unstable ASCVD; ACS within 60 days is typically a relative exclusion for new initiation pending CV stabilization.
• NT-proBNP or BNP if HFpEF-suspect (obesity + dyspnea on exertion + age ≥60). Anchors HFpEF investigational-extension eligibility framing per §1.3.
• Echocardiogram if HFpEF-suspect. LV ejection fraction, diastolic-function indices, LV-mass index.
• High-sensitivity CRP (hsCRP, CPT 86141; Medicare $12.95; DTC $79 single-source). Cardiovascular inflammation marker; informs SELECT-population CV risk stratification.
• Carotid intima-media thickness or CAC score if subclinical ASCVD assessment is part of the practice’s CV-risk workflow. Not required by trial-program enrollment but commonly included in modern practice for risk stratification.

3.7 Organ-baseline panels (thyroid, pancreas, ophthalmology — class-wide for GLP-1 RAs)

Class-wide pre-treatment workup for every semaglutide patient regardless of indication. Anchors to §2.4 contraindications and to §6 AE-management algorithms.

Thyroid baseline. TSH at minimum; neck examination for thyroid nodules. If personal or family history of MTC or MEN-2 is identified at this step, this is a §2.4 hard contraindication and the protocol does not initiate.

• Calcitonin (CPT 82308; Medicare $26.79) — if MTC / MEN-2 family history present, calcitonin baseline obtained; serial monitoring per endocrinology specialist consultation. routine calcitonin screening is not generally recommended in average-risk patients — the boxed warning is based on rodent C-cell signal (Bjerre Knudsen 2010, PMID 20203154; species-specific to rodents, does not translate to primates); routine calcitonin screening has high false-positive rate without proportionate predictive value. Clinician-judgment, not protocol-mandated, for average-risk patients.

Pancreas baseline. Serum lipase (CPT 83690; Medicare $6.89; DTC 35–39), serum amylase (CPT 82150; Medicare $6.48; DTC $28). Lipase is more pancreas-specific. Triglycerides per §3.2 lipid panel (hypertriglyceridemic pancreatitis is a distinct etiology). Pancreatitis-history documentation per §2.4. not recommended as routine asymptomatic monitoring — baseline reference + clinical-trigger-based serial measurement.

Ophthalmology — dilated retinal examination. Particularly for T2D patients per §3.3 diabetes-complication-screen overlap and per the SUSTAIN-6 retinopathy-complication signal in rapid-HbA1c-improvement sub-population. Pre-treatment dilated exam for any T2D patient with HbA1c ≥9.0 or with known background DR is the protocol-recommended posture.

NAION pre-screen (semaglutide-specific signal under evaluation).EMA-labeled “very rare” per EMA PRAC June 2025 (~1 case per 10,000 person-years; ~two-fold increase vs non-users); FDA has not updated US labels as of 2026-05-13 — US/EU labeling divergence. Multiple converging lines of evidence (Hathaway 2024 PMID 38958939; Grauslund Danish nationwide PMID 39696569; Lakhani 180-country pharmacovigilance PMID 40383360; Cheng 2026 PMID 41021211; Vilsbøll EASD 2025). Class-differentiated to semaglutide; tirzepatide signal absent at same threshold per PMID 40383360. Clinician-judgment includes pre-treatment screen for known optic-disc cupping (small or “disc-at-risk”), prior NAION, or unexplained visual symptoms.

3.8 Body-composition baseline

Applies to every CWM patient and to lean-mass-stack co-prescription contexts (§9.3).

• Bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA). Lean mass, fat mass, visceral adipose tissue if DEXA. DEXA is more accurate; BIA is more accessible.
• Hand-grip strength or sit-to-stand timed test. Functional strength baseline — particularly relevant for ≥65 age phenotype where sarcopenia risk during weight loss is a clinical concern.
• Resting energy expenditure (REE) if indirect-calorimetry-equipped. Establishes energy-expenditure phenotype baseline (§1.4 taxonomy).

3.9 Indication-by-indication worked panel inventory

The pre-treatment panel composition varies by indication. Worked-example panels:

Non-diabetic adult initiating Wegovy 2.4 mg for CWM (most common semaglutide initiation phenotype). Standard metabolic panel (§3.2), thyroid + pancreas baseline (§3.7), ophthalmology dilated exam if any visual-symptom history or first-degree NAION family history (§3.7), body-composition BIA or DEXA (§3.8). MASH-risk screen via FIB-4 calculation from standard panel; advance to elastography only if FIB-4 indeterminate or high.

T2D adult initiating Ozempic for glycemic control. Standard panel + diabetes-specific panel (§3.3) including fasting C-peptide and dilated retinal exam, with HbA1c-determined urgency on the retinal exam (pre-treatment for HbA1c ≥9.0; within 6–12 months otherwise). UACR documented for FLOW-eligible kidney-risk co-stratification regardless of CKD indication. Thyroid + pancreas baseline (§3.7); NAION pre-screen.

Adult with established CVD initiating Ozempic for SUSTAIN-6 / SELECT CV-risk indication. Standard panel + CV-risk panel (§3.6): ECG baseline; troponin if symptomatic; echocardiogram if HFpEF-suspect; hsCRP for CV-risk stratification; carotid IMT or CAC if practice workflow. Plus thyroid + pancreas baseline (§3.7); NAION pre-screen.

Adult with confirmed MASH F2–F3 initiating Wegovy for ESSENCE-anchored MASH indication. Standard panel + full MASH-specific panel (§3.4) — AST/ALT, GGT, platelet count, FIB-4, VCTE / FibroScan; viral hepatitis screen; iron studies; autoimmune liver-disease screen if clinically indicated. Liver biopsy if histologic staging is needed or alternative liver disease must be ruled out. Hepatology co-management if F3 fibrosis or above. Plus organ-baseline (§3.7); NAION pre-screen.

Adult with T2D and CKD initiating Ozempic for FLOW-anchored CKD-in-T2D indication. Standard panel + diabetes panel (§3.3) + full kidney-specific panel (§3.5) — UACR documentation, cystatin-C-eGFR if discordant, RAS-blockade documentation at maximally tolerated dose, CKD-MBD panel if eGFR <60. Nephrology co-management for advanced CKD. Plus organ-baseline (§3.7).

Adolescent ≥12 initiating Wegovy for STEP TEENS-anchored CWM indication. Standard panel + thyroid + pancreas baseline (§3.7); pediatric obesity-medicine specialist co-management; growth and developmental baseline; psychosocial baseline. Reproductive-age-female-specific counseling on contraception per §6.10 oral contraceptive absorption considerations.

Polycondition adult (T2D + obesity + ASCVD + CKD + possible MASH). Combined panel: standard + diabetes-specific + kidney-specific + CV-risk-specific + organ-baseline + body-composition + FIB-4 / elastography if MASH-risk profile present. Often satisfies multiple indication criteria simultaneously (see §12.4 worked case for this phenotype).

3.10 Pre-treatment workup-to-monitoring reconciliation

Every lab in §3 is mapped to its §5 maintenance monitoring cadence and to its §6 AE-trigger role:

Lab	Baseline (§3)	Maintenance interval (§5)	AE-trigger role (§6)
HbA1c	All T2D / glycemic-context	Quarterly Y1; biannual thereafter	Hypoglycemia screen w/ insulin/SU
CMP	All patients	Every 3–6 months titration; annually maintenance	eGFR monitoring; LFT
Lipid panel	All patients	Every 6–12 months	CV trajectory
TSH	All patients	Annual or symptom-prompted	Thyroid context (MTC contraindication ruling)
Lipase	Symptomatic / risk-prompted	Symptom-prompted only (NOT routine)	§6.4 pancreatitis algorithm trigger
UACR / eGFR	All T2D and all eGFR 30–60	Quarterly Y1 if CKD indication; annual otherwise	Kidney function trajectory
AST/ALT/FIB-4	All MASH-risk profile	Annual or per hepatology recommendation	LFT abnormality trigger
Dilated retinal exam	All T2D HbA1c ≥9.0; visual-symptom hx	Annual or per ophthalmology	Retinopathy worsening + NAION trigger
Body composition (BIA/DEXA)	All CWM	Quarterly Y1; biannual thereafter	Lean-mass-loss trigger → §9.3 stack
BP	All patients	Every visit	Hypertension co-medication adjustment
Weight	All patients	Every visit	Effect-size trajectory; non-response §7

Lipase rationale. Lipase is monitored on symptom-prompted basis (abdominal pain), not on scheduled-interval basis, per the AC2-26 system-observations precedent on not screening with low-specificity labs absent symptom. Routine asymptomatic lipase monitoring has high false-positive rate without proportionate predictive value.

---

4. Initiation protocol

4.1 Purpose

Define the starting dose, titration schedule, and tolerability-management cadence for semaglutide initiation. §4 is the time-sequenced action plan from Day 0 (first dose) through approximately Week 16–20 (target-dose attainment for Wegovy 2.4 mg CWM patients) — the period during which the patient transitions from naive to maintenance-stable.

The initiation period is when patient adherence is most fragile, GI tolerability is most challenging, and clinician counseling has the greatest influence on continuation vs discontinuation.does before what initiation avoids (rapid titration, GI AE escalation, adherence failure).

4.2 Starting doses by formulation

Starting doses are tolerability-priming, sub-therapeutic by design — they are not effect-target doses. Anchors per canonical §8.1.

Ozempic (T2D, CV, CKD, PAD indications): 0.25 mg SC weekly × 4 weeks.

Wegovy SC (CWM, CV in non-diabetic obesity, MASH, adolescent ≥12): 0.25 mg SC weekly × 4 weeks.

Wegovy HD 7.2 mg (post-tolerance escalation only): Not a starting dose. Requires completion of standard Wegovy titration to 2.4 mg and tolerance for ≥4 weeks. Specific 2.4 → 7.2 mg transition schedule per FDA Prescribing Information; do not jump to 7.2 mg without prior 2.4 mg tolerance.

Rybelsus (oral T2D; T2D + ASCVD/CKD CV per SOUL): 3 mg PO daily × ~30 days. SNAC absorption discipline required from day 1 — empty stomach upon waking, ≤120 mL water, 30-minute pre-food window.

Oral Wegovy 25 mg (CWM, August 2025 approval): Initiation per FDA label; titration discipline parallel to Rybelsus daily-oral absorption requirements.

4.3 Titration schedules

Wegovy SC standard titration:

Weeks	Dose	Purpose
1–4	0.25 mg/week	GI tolerability initiation
5–8	0.5 mg/week	Dose escalation
9–12	1.0 mg/week	Dose escalation
13–16	1.7 mg/week	Dose escalation
17+	2.4 mg/week	Maintenance dose (standard CWM target)

Total titration period: 16 weeks; Week 17 is the first target-dose week.

Ozempic SC titration (T2D standard): 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg (target for SUSTAIN-6 / FLOW / STRIDE). Escalation to 2.0 mg permitted if HbA1c target not met and tolerability allows (SUSTAIN-FORTE basis).

Rybelsus titration (T2D): 3 mg × ~30 days → 7 mg → 14 mg (target for SOUL CV-outcome indication) → 25 mg if higher dose indicated (PIONEER PLUS basis).

Wegovy HD 7.2 mg titration (post-2.4 mg tolerance): Specific 2.4 → 7.2 mg transition per FDA PI; clinician judgment within label on pace.

Slow-titration option (extended interval). Each 4-week step extended to 6–8 weeks for patients with marginal GI tolerability. A patient on slow titration is not on a different protocol; they are on the standard protocol with a stretched timeline. Real-world dosing patterns confirm this is established clinical practice; faster escalation has no demonstrated benefit and predictable tolerability cost.

Steady-state rationale. Semaglutide half-life ~7 days; ~4–5 weeks required to reach steady state at each dose level. The 4-week step schedule aligns with this pharmacokinetic floor. Step-back maneuvers (return to prior dose then re-escalate) when GI tolerability fails at a given dose are real-world established practice; no published evidence-based step-back protocol but clinical judgment per established framework.

4.4 GI tolerability management at each titration step

Anticipatory framing: GLP-1 RA-mediated delayed gastric emptying, central appetite-pathway modulation, and direct GI-motility effects produce a characteristic AE profile peaking at each dose escalation and typically attenuating within 2–4 weeks at stable dose.

Trial-program prevalence anchors:

• Nausea: 20–44% across STEP and SUSTAIN trials (~44% semaglutide vs ~18% placebo in STEP-1)
• Vomiting: 10–25% (~24% vs ~6%)
• Diarrhea: 15–30% (~32% vs ~16%)
• Constipation: 10–24% (~24% vs ~11%)
• Discontinuation due to GI AE in STEP-1: ~4.5% of semaglutide arm
• Huang 2024 meta-analysis (PMID 38787986): extended treatment duration (>30 weeks) associated with decreased incidence of GI events — self-limiting profile during titration

First-line management — non-pharmacologic:

• Reduce meal size; slow eating pace
• Avoid greasy / high-fat meals
• Hydrate consistently
• Separate medication-and-meal timing for oral semaglutide (PIONEER PPI / 30-minute window counseling)
• Patient education: GI AE is expected at titration, typically attenuates; this is not failure

First-line management — pharmacologic:

• Nausea: Ondansetron 4 mg PRN; consider scheduled dosing for moderate-severity nausea recurring 2–3 days post-injection. Cross-reference QT considerations in concurrent medications.
• Vomiting: Distinguish protocol-related vomiting (expected, attenuates) from acute-pancreatitis-suspect vomiting (severe abdominal pain, persistent, with lipase elevation) — §6.4 algorithm.
• Diarrhea: Loperamide PRN per standard dosing; hydration emphasis.
• Constipation:
• Eructation (“sulfur burps”): Recognized semaglutide-specific AE most commonly reported at 1.0–2.4 mg doses; reassurance and food-pairing adjustments are first-line.

Volumetric titration adjustment. Persistent moderate-to-severe GI AE at any step is the trigger for slow-titration (§4.3) — hold at current dose for an additional 2–4 weeks before next escalation, or step back to prior dose if tolerability does not stabilize.

Acute kidney injury secondary to dehydration is a recognized rare event from severe GI AE; hydration counseling is part of standard initiation discipline.

4.5 Early monitoring cadence

The early-monitoring cadence is the contact frequency during the initiation period. Typical Wegovy CWM cadence: Week 2 (post-first-dose tolerability check; telehealth modality acceptable), Week 5–6 (post-first-titration; in-person or telehealth, with weight and BP), Week 9–12 (mid-titration tolerability + adherence + weight + BP), Week 17–20 (target-dose attainment confirmation + transition to §5 maintenance cadence).

For T2D-indication initiation (Ozempic), add HbA1c reassessment at Week 12–16; semaglutide HbA1c effect plateau is typically reached by Week 26–30, so an interim Week 12–16 trajectory check informs dose-vs-target decision-making.

Contact modality (in-person vs telehealth vs message) is practice-specific. Escalation triggers (any contact identifying severe GI AE, suspected pancreatitis, suspected gallbladder event, suspected NAION, or significant unintended weight loss exceeding protocol target trajectory → in-person evaluation within 48 hours).

4.6 Step-specific worked patient profiles

0.25 mg Week 1 first-dose AE profile. Nausea is the most common early AE — typically mild and self-limited within 5–7 days for many patients; moderate or persistent nausea triggers ondansetron 4 mg PRN and reinforcement of meal-size and meal-composition counseling. A patient experiencing mild nausea on day 3 post-first-dose is on-trajectory; reassurance and continued titration are appropriate.

0.5 mg Week 5 first-escalation profile. Most common challenge step. Nausea recurrence on dose increase is anticipated and counseled-for. If moderate-severity nausea persists beyond 2 weeks at 0.5 mg, hold for an additional 2–4 weeks before escalating to 1.0 mg (slow-titration de facto applied at this specific step). Patient counseling: this is the most common challenge step, not a failure pattern.

1.0 mg / 1.7 mg / 2.4 mg subsequent escalations. Follow the same hold-if-needed logic. Eructation (“sulfur burps”) most commonly reported at 1.0–2.4 mg doses.

2.4 → 7.2 mg Wegovy HD escalation profile. Only after ≥4 weeks tolerance of 2.4 mg without major GI breakthrough. Specific FDA PI schedule applies. Defining new AE at 7.2 mg: dysesthesia in 22.9% of 7.2 mg participants vs 0.5% placebo in STEP UP non-T2D (PMID 40961952); 18.9% vs 4.9% in STEP UP T2D (PMID 40961953). Counsel patients explicitly about altered skin sensation (tingling, burning, numbness); document baseline neurologic exam before escalation; plan dose reduction or discontinuation if dysesthesia is severe or persistent. dysesthesia is a known reversible AE, not progressive nerve damage — canonical §12.10 Pattern 9 framing.

4.7 Slow-titration variant — when to default to it

Default to slow-titration (each 4-week step extended to 6–8 weeks) for:

• Patients with prior GI sensitivity (history of IBS, GERD with severe symptoms, prior intolerance of any anti-obesity medication on GI grounds)
• Older adults (≥65) with multimorbidity
• Patients with concurrent medications that may compound GI effects
• Patients whose Week 2 first-dose telehealth check reveals moderate-severity GI AE

Slow-titration is clinician-judgment-within-label, not off-label. The patient and clinician decide; the timeline is stretched but the operational endpoints (target dose, target effect, maintenance transition) are the same.

4.8 Patient counseling at initiation (cross-reference §10.2)

Required counseling beats at initiation per §10.2:

• What semaglutide is, plain-language mechanism, indication-specific expected effect-size
• Titration schedule (standard and slow-titration options; patient informed timeline is adjustable to tolerability)
• AE profile expected at each titration step (nausea is anticipated, attenuates; reassurance that AE-emergence is not failure)
• Pre-conception planning beat for reproductive-age patients (verbatim Anchor 3 framing in §10.4)
• Cost / access realities (verbatim Anchor 1 + 2 framing on compounded-vs-FDA-approved if applicable per §10.3)
• Escalation pathway: symptoms warranting in-person evaluation within 48 hours
• Comparator-class framing if patient asks about tirzepatide / retatrutide / orforglipron alternatives (verbatim Anchor 4 framing in §10.5)

5. Maintenance protocol

5.1 Purpose

Define the post-titration, target-dose-attained operating state of the semaglutide protocol: target dose, monitoring intervals, dose-adjustment triggers, and the transition between maintenance and discontinuation (§8) or non-response algorithm (§7). §5 is the longest operational phase of a semaglutide protocol — for a CWM patient who tolerates target dose and continues therapy, maintenance is open-ended for the duration of clinical benefit.

The chronic-therapy framing is load-bearing. STEP-4 (PMID 33755728) and STEP-1 Extension (PMID 35441470) demonstrated two-thirds of weight loss regained within 12 months of discontinuation. SELECT 4-year durability (Ryan 2024, PMID 38740993) demonstrated –10.2% mean weight loss maintained at 208 weeks with continued therapy. Informed consent at initiation must explicitly address indefinite-treatment expectation.

5.2 Target doses by indication

Indication	Target dose	Trial anchor
CWM, non-diabetic adults	Wegovy 2.4 mg SC weekly	STEP-1 PMID 33567185
CWM, higher-dose (post-2.4 mg tolerance, not at goal)	Wegovy HD 7.2 mg SC weekly	STEP UP PMID 40961952
CWM, adolescent ≥12	Wegovy 2.4 mg SC weekly	STEP TEENS PMID 36322838
CWM, oral platform	Oral Wegovy 25 mg PO daily	OASIS 4 PMID 40934115
T2D glycemic control	Ozempic 1.0 mg SC weekly (escalate to 2.0 mg if needed)	SUSTAIN program; SUSTAIN-FORTE for 2.0 mg
T2D oral	Rybelsus 14 mg PO daily (escalate to 25 mg if needed)	PIONEER program; PIONEER PLUS PMID 37385279
T2D + ASCVD/CKD CV risk (oral)	Rybelsus 14 mg PO daily	SOUL PMID 40162642
T2D + CVD MACE reduction	Ozempic 1.0 mg SC weekly	SUSTAIN-6 PMID 27633186
T2D + CKD kidney composite	Ozempic 1.0 mg SC weekly	FLOW PMID 38785209
T2D + PAD walking capacity	Ozempic 1.0 mg SC weekly	STRIDE PMID 40169145
CV risk reduction, non-diabetic obesity + CVD	Wegovy 2.4 mg SC weekly	SELECT PMID 37952131
MASH F2/F3	Wegovy 2.4 mg SC weekly	ESSENCE PMID 40305708
HFpEF + obesity (off-label / investigational)	Wegovy 2.4 mg SC weekly	STEP-HFpEF program (label expansion pending)

Each target dose is anchored to a specific trial enrollment population. The 2.0 mg Ozempic dose was approved following SUSTAIN-FORTE and offers incremental HbA1c reduction at the cost of additional GI AE; the choice between 1.0 mg and 2.0 mg is HbA1c-trajectory- and tolerability-determined, not default-escalation. For CKD-in-T2D indication (FLOW), 1.0 mg is the trial-enrollment dose; escalation to 2.0 mg is permitted if HbA1c target not met and tolerability allows, but the kidney-outcome data is anchored to the 1.0 mg enrollment.

5.3 Monitoring intervals

Monitoring intervals for the maintenance phase are typically: 3-month visits during the first year on target dose, 6-month visits thereafter for stable patients. The exact cadence depends on indication and on baseline comorbidity burden — a T2D patient with active diabetic nephropathy on FLOW-anchored protocol may have more frequent monitoring than a non-diabetic CWM patient on Wegovy with no comorbidity.

Monitoring panel at each interval:

• Weight + BP — every visit.
• HbA1c (CPT 83036): every 3 months during titration and first year of maintenance for T2D / glycemic-context indications; extend to every 6 months once stable. Frequency anchored in STEP program (baseline, week 20, week 36, week 52, week 68 in STEP-1) and SUSTAIN program (baseline, week 16, week 32, week 56, week 104).
• CMP (CPT 80053): every 3–6 months during titration; annually during stable maintenance.
• Lipid panel (CPT 80061): every 6–12 months.
• UACR + eGFR: annually for routine; quarterly Y1 if CKD indication or borderline kidney baseline; closer if FLOW-anchored CKD protocol.
• AST/ALT/FIB-4 trajectory: annual for MASH-risk profile; per hepatology recommendation if MASH indication.
• Body composition (BIA / DEXA): quarterly Y1 in CWM patients to track lean-mass-loss vs total-weight change; biannual thereafter.
• Symptom-prompted labs: lipase if abdominal pain (§6.4 algorithm); calcitonin per endocrinology consultation if MTC family history baseline-positive; troponin / ECG if cardiac symptoms.

Annual maintenance panel cost summary: Medicare allowable 73.95(HbA1c × 4 + CMP × 2 + lipid × 1); DTCself − pay(mediansingle − source) 203.

Frequency rationale anchored in trials: STEP program protocols established quarterly weight + visit cadence; SUSTAIN program established quarterly HbA1c monitoring through Year 1 then biannual; SELECT enrolled with HbA1c, CMP, lipid panel at baseline + annually with intensive AE monitoring.

5.4 Dose-adjustment triggers

Three trigger categories: target-not-met (effect is sub-threshold for clinical benefit), target-overshoot (effect exceeds clinical target — typically relevant for T2D glycemic-overshoot with hypoglycemia risk), and AE-emergent (new or worsening AE that responds to dose adjustment).

Dose-adjustment options: hold dose (maintain current); titrate up (move to next label-permitted dose if not at maximum); titrate down (move to prior dose for tolerability); transition to §7 non-response algorithm if maximum dose with appropriate trial duration has not produced clinical benefit.

CWM (Wegovy 2.4 mg) dose-adjustment triggers:

• Target-not-met: <5% weight loss at Month 6 on 2.4 mg with documented adherence → §7 non-response algorithm; consider Wegovy HD 7.2 mg escalation (post-tolerance criteria), tirzepatide transition, or CagriSema if available.
• Target-overshoot: Unintended weight loss below patient’s pre-specified target floor (e.g., BMI dropping below 22 in non-athletic patient; clinician-judgment threshold per patient body-composition baseline) → dose-down to 1.7 mg or 1.0 mg with re-evaluation.
• AE-emergent: Persistent moderate-severity GI AE on 2.4 mg unresponsive to symptomatic management → dose-down to 1.7 mg with Month 3 reassessment for whether 1.7 mg maintains adequate effect.

T2D (Ozempic) dose-adjustment triggers:

• Target-not-met: HbA1c above individualized target (typically <7.0% per ADA/EASD individualized targets) at Month 6 on 1.0 mg → escalate to 2.0 mg consideration; persistent above-target HbA1c at 2.0 mg → §7 non-response (transition to tirzepatide per SURPASS-2 head-to-head; add SGLT2 inhibitor; add insulin per ADA/EASD).
• Target-overshoot: Hypoglycemia risk on concurrent insulin or sulfonylurea is the most common overshoot pattern; protocol typically titrates down the concurrent agent rather than down-titrating semaglutide.
• AE-emergent: Per CWM logic above.

Wegovy HD 7.2 mg dose-adjustment triggers (post-tolerance maintenance):

• Target-not-met: If <5% additional weight loss beyond 2.4 mg trajectory at Month 3–6 on 7.2 mg with documented adherence → reassess phenotype; consider transition options per §7.
• AE-emergent (dysesthesia specifically): Dysesthesia 22.9% in 7.2 mg (PMID 40961952); document baseline neurologic exam; severe or persistent dysesthesia → dose-down to 2.4 mg with reassessment. Patient counseling: not progressive nerve damage; reversible with dose reduction.

Maintenance-at-lower-dose pattern. Maintenance at 1.7 mg weekly rather than 2.4 mg in patients achieving target weight at lower dose is observed in clinical practice. This is clinician-judgment-within-label, not a separate FDA-approved pattern; the evidence base for sustained lower-dose maintenance is limited.

5.5 Indication-specific maintenance trajectories

CWM trajectory:

• ≥5% weight loss by Week 16–20 expected on 2.4 mg
• ≥10% by Week 32–40
• ≥15% by Week 52–68 (full STEP-1 trajectory)
• Failure to achieve ≥5% by Week 20 at 2.4 mg with adequate adherence → §7 non-response algorithm

T2D glycemic trajectory:

• HbA1c reduction ≥1.0% typically expected by Week 26–52 of maintenance dosing
• Failure to achieve HbA1c reduction ≥0.5% by 26 weeks at maintenance dose → reassessment (adherence, dose, mechanism alternative)

CV risk reduction (SELECT context):

• MACE reduction is population-level outcome demonstrated over 39.8-month mean follow-up; not assessable per individual patient on short timeframe
• Surrogate markers: weight loss trajectory, BP improvement, hsCRP reduction, lipid trajectory — all support continued therapy when present

CKD trajectory (FLOW context):

• Slowing of eGFR decline trajectory over 12–24 months — assessable per individual patient through serial eGFR
• Microalbumin reduction or stabilization

MASH trajectory (ESSENCE context):

• LFT trajectory (ALT/AST normalization expected over 12+ months)
• FibroScan trajectory (decreasing kPa)
• Re-biopsy or imaging confirmation per hepatology recommendation at ~72 weeks per ESSENCE primary-endpoint timeline if clinically indicated

5.6 Maintenance phase patient experience anchors

Anticipatory framing for the maintenance period:

• Plateau is biology, not failure (§7.3 set-point framing). Weight stability at a new lower baseline is the protocol-typical maintenance outcome; ongoing pharmacologic support is what holds the new equilibrium.
• GI AE attenuation.
• Indefinite-therapy framing. Discontinuation produces predictable weight regain (~two-thirds at 12 months) and cardiometabolic-marker reversal; maintenance therapy is the operational anchor for sustained benefit (§8.5 framing).
• Comparator-switch pathway available. If maintenance trajectory plateaus below target or AE profile becomes unacceptable, transition to tirzepatide (or pending-approval retatrutide / orforglipron / CagriSema) is a legitimate clinical option (§7 non-response algorithm).

5.7 Worked maintenance scenarios

Scenario A — Wegovy 2.4 mg CWM patient at Month 12 on target dose. A 47-year-old female, baseline BMI 33, has lost 14.5 kg (~14% of starting weight, on-trajectory for STEP-1 effect-size). GI AE attenuated by Month 8; mild recurring 2–3-day post-injection nausea remains. BP improved from 138/86 to 122/78. Body composition: lean mass loss ~22% of total weight loss (within typical proportion). Protocol response: continue 2.4 mg; quarterly visits with weight + BP + body composition; annual HbA1c + lipid + UACR. Counseling beat: maintenance trajectory is on-target; chronic therapy framing reinforced.

Scenario B — Ozempic 1.0 mg T2D patient at Month 6. A 58-year-old male, T2D + established CVD, on Ozempic 1.0 mg from SUSTAIN-6 indication. HbA1c at Month 6: 7.4 (above individualized target 7.0). Weight –8 kg from baseline. No hypoglycemia events on concurrent metformin only. Protocol response: escalate to 2.0 mg (SUSTAIN-FORTE basis); reassess HbA1c at Month 9. Continue quarterly visits.

Scenario C — FLOW-anchored CKD-in-T2D patient at Month 12. A 63-year-old male, T2D + CKD eGFR 42 + UACR 280, on Ozempic 1.0 mg + maximally tolerated ARB. eGFR at Month 12: 41 (slope –1/year, slower than pre-treatment –4/year trajectory). UACR 180 (reducing). HbA1c 6.9. Protocol response: continue 1.0 mg; quarterly eGFR + UACR + HbA1c; annual lipid. Add SGLT2 inhibitor consideration per ADA/EASD polycondition algorithm (§9.2). Counseling beat: kidney trajectory is on-target; CKD progression slowed.

Scenario D — ESSENCE-anchored MASH F3 patient at Month 18. A 51-year-old female, MASH F3 + obesity BMI 34, on Wegovy 2.4 mg from ESSENCE indication. Month 18 LFT: ALT 32 (from 84 baseline); AST 28 (from 62). FibroScan 8.2 kPa (from 12.4). Weight –13 kg. Hepatology co-management ongoing; re-biopsy not pursued given non-invasive evidence of fibrosis improvement. Protocol response: continue 2.4 mg; biannual LFT + FibroScan; hepatology continues co-management.

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the adverse-event categories that apply to semaglutide. §6 is the AE-by-AE-class operational reference — what to expect, when to escalate, when to discontinue. The section is structured by AE class with each addressed in a standard sub-structure: anticipatory framing → identification → severity grading → first-line management → escalation triggers → discontinuation triggers.

Opening with discontinuation triggers would steer clinicians (and through training materials, patients) toward fear-framed AE response rather than expectation-anchored response.

6.2 GI AE class — the dominant AE category

Anticipatory framing. GLP-1 RA-mediated delayed gastric emptying, central appetite-pathway modulation, and direct GI-motility effects produce a characteristic AE profile: nausea, vomiting, diarrhea, constipation, eructation, abdominal pain. Peak at dose escalation; typically attenuates within 2–4 weeks at stable dose. Huang 2024 meta-analysis (PMID 38787986): extended treatment duration (>30 weeks) associated with decreased GI event incidence.

Trial-program prevalence anchors:

• Nausea: 20–44%
• Vomiting: 10–25%
• Diarrhea: 15–30%
• Constipation: 10–24%
• Discontinuation due to AE across STEP and SUSTAIN: 6–9% primarily GI-driven

Identification. Patient-reported during early-monitoring contacts (§4.5) and maintenance visits (§5.3). CTCAE severity grading: Grade 1 (mild, intervention not indicated); Grade 2 (moderate, minimal intervention); Grade 3 (severe, hospitalization); Grade 4 (life-threatening). Most protocol-relevant GI AEs are Grade 1–2.

First-line management. Non-pharmacologic: meal-size reduction, slow eating pace, low-fat / non-greasy meal composition, hydration emphasis, separation of medication-and-meal timing for oral semaglutide.

Escalation triggers. Grade 3 severity at any step. Persistent Grade 2 beyond 4 weeks at stable dose. Vomiting with severe abdominal pain → assess for pancreatitis (§6.4). Significant unintended weight loss exceeding protocol target trajectory.

Discontinuation triggers. Grade 3 GI AE that does not resolve with dose-down. Patient preference. Persistent severe AE in pre-procedural / peri-surgical contexts may warrant temporary discontinuation per anesthesia / surgical-team consultation.

6.3 Pancreatitis AE class

Anticipatory framing. Wen 2025 systematic review (PMID 40988099; 62 RCTs, n=66,232): pooled RR 1.44 (95% CI 1.09–1.89, p=0.009) for acute pancreatitis — modest signal; absolute event rates remain low (<1–2% per year); authors frame as “slightly increased risk, likely minimal.” Pivotal trials (SUSTAIN, STEP, SELECT, FLOW, ESSENCE) did not demonstrate a statistically significant pancreatitis-incidence signal in individual trial populations beyond placebo. the signal exists at the meta-analysis level; absolute risk to the individual patient is small. severe prior pancreatitis history is labeled cautionary use / precaution, not labeled-as-absolute-contraindication (per current label).

Identification. Symptom-prompted — persistent severe upper abdominal pain radiating to back, often with vomiting, often worse with food. Differential: GI AE class (§6.2) does not typically produce severe persistent localized pain; protocol differentiates “GI AE expected at titration” from “pancreatitis-suspect abdominal pain” via persistence, severity, localization, and lipase.

First-line management. Acute persistent severe abdominal pain with vomiting → immediate evaluation, lipase + amylase + CMP + CBC + lipid panel (rule out hypertriglyceridemic pancreatitis), abdominal imaging (CT or MRCP). Discontinue semaglutide pending evaluation.

Escalation triggers. Confirmed acute pancreatitis (clinical + lab + imaging) → hospitalization; supportive management per pancreatitis standard-of-care. Severity stratification via Ranson / BISAP / APACHE-II.

Discontinuation triggers. Confirmed acute pancreatitis attributable to semaglutide (excluding alternative etiology — gallstones, hypertriglyceridemia, alcohol) → permanent discontinuation; transition to non-GLP-1 alternative if Module 5 indication continues.

6.4 Gallbladder AE class

Anticipatory framing. Cholelithiasis / cholecystitis trial-program prevalence 1–3% across STEP and SUSTAIN. Mechanism: rapid weight loss elevates gallstone risk through cholesterol supersaturation in bile + possibly direct effects on gallbladder motility. Higher dose and faster weight-loss trajectory associate with higher gallbladder event rate. Pre-existing gallbladder disease is relative consideration.

Identification. Symptom-prompted — right upper quadrant pain, post-prandial colicky pain, fever-and-pain combination. Ultrasound is first-line imaging; HIDA scan if functional cholecystitis suspected without stones.

First-line management. Symptomatic gallstones with confirmed cholelithiasis and symptoms compatible with biliary colic → surgical consultation; typical management trajectory is laparoscopic cholecystectomy. Protocol decision: temporary hold during peri-operative window; resume at maintenance dose post-cholecystectomy if no other contraindication has emerged.

Escalation triggers. Acute cholecystitis with systemic signs (fever, leukocytosis, sepsis). Choledocholithiasis suspected (LFT pattern + dilated CBD on imaging) → urgent ERCP or surgical consultation.

Discontinuation triggers. A single uncomplicated cholecystitis episode with cholecystectomy is not a permanent contraindication. Recurrent symptomatic post-cholecystectomy bile-acid-related pattern: clinician judgment for protocol continuation vs alternative-molecule transition.

6.5 Diabetic retinopathy worsening AE class (T2D context)

Anticipatory framing. Class-level signal observed in SUSTAIN-6 (PMID 27633186) in patients with pre-existing retinopathy and rapid glycemic improvement — mechanism hypothesized as glycemic-improvement-mediated rather than direct GLP-1R-mediated retinal toxicity. signal is anchored to the rapid-HbA1c-improvement sub-population; direction-of-effect in the non-DR or mild-DR sub-population is not established as protective or harmful.

Identification. Vision change reports; scheduled ophthalmology surveillance per §3 baseline frequency.

First-line management. Ophthalmologic baseline before initiation in patients with known retinopathy or long-standing T2D; gradual titration to mitigate rapid glycemic improvement (the same titration framework used for tolerability also moderates rate of glycemic improvement); co-management with ophthalmology.

Escalation / discontinuation triggers. Active proliferative DR worsening on therapy → ophthalmology co-management; clinician judgment on continuation vs alternative therapy depending on severity and ophthalmology recommendation. Not an automatic discontinuation but warrants close co-management.

6.6 NAION AE class — semaglutide-specific signal under evaluation

Anticipatory framing. Non-arteritic anterior ischemic optic neuropathy signal in semaglutide pharmacovigilance is supported by multiple converging lines of evidence:

• Hathaway 2024 JAMA Ophthalmol (PMID 38958939) single-center cohort: HR 4.28 (95% CI 1.62–11.29) in T2D; HR 7.64 (95% CI 2.21–26.36) in overweight/obese
• Grauslund 2024 Danish nationwide cohort n=424,152 (PMID 39696569): HR 2.19 (95% CI 1.54–3.12) at 5 years
• Lakhani 2025 180-country pharmacovigilance (PMID 40383360): FAERS ROR 11.12; VigiBase ROR 68.58; no significant NAION signal for tirzepatide at the same threshold — class-differentiated to semaglutide
• Cheng 2026 multi-database pharmacovigilance (PMID 41021211): FAERS + VigiBase confirmation
• Vilsbøll EASD 2025 late-breaker — pooled-trial NAION incidence

EMA PRAC June 2025 classified NAION as “very rare” side effect (~1 case per 10,000 person-years; ~two-fold increase vs non-users). FDA has not updated US labels as of 2026-05-13 — US/EU labeling divergence. Regardless of FDA label status, clinicians should counsel patients on the NAION pharmacovigilance signal, particularly those with known ophthalmic risk factors (crowded optic disc, history of NAION in fellow eye, hypertension, sleep apnea, dyslipidemia).

Identification. Acute monocular vision loss, typically painless, often altitudinal visual field defect. Optic disc edema on exam in the acute phase. Differential: giant cell arteritis (arteritic AION, separate entity — distinguish via ESR/CRP); retinal vascular occlusion; optic neuritis.

First-line management. Urgent ophthalmology evaluation. Discontinue semaglutide pending evaluation. ESR + CRP to rule out arteritic etiology.

Escalation / discontinuation triggers. Confirmed NAION → permanent discontinuation regardless of indication continuation. Ophthalmology co-management for fellow-eye monitoring (post-NAION fellow-eye recurrence is the established counseling beat post-event). The patient and clinician decide whether to attempt an alternative GLP-1 RA or transition to non-GLP-1 weight-management approach.

6.7 Cancer-context surveillance

Anticipatory framing. The 2026 definitive cancer SR (Ko et al Annals Intern Med 2026, PMID 41359966; n=94,245 across 48 RCTs) characterizes GLP-1 RA effects on 11 cancer types + multiple myeloma + meningioma:

• Moderate-certainty “little or no effect”: thyroid, pancreatic, breast, kidney
• Low-certainty “may have little or no effect”: colorectal, esophageal, liver, gallbladder, ovarian, endometrial, multiple myeloma, meningioma
• Gastric: very uncertain
• Overall: “GLP-1RAs may have little or no effect on risk for obesity-related cancers.”

Per-context surveillance posture:

• MTC and MEN-2 family history (§2.4 hard contraindication territory): screen before prescribing; calcitonin baseline if positive history; serial monitoring per endocrinology consultation. Routine asymptomatic patients do not need calcitonin monitoring. The boxed warning rests on rodent C-cell mechanism (Bjerre Knudsen 2010, PMID 20203154) that is species-specific; human MTC signal is debated; 2026 SR characterizes thyroid cancer signal as moderate-certainty “little or no effect.”
• Pancreatic cancer: risk-stratified per Section 5.3 framework; not routine screening. CA 19-9 (CPT 86301) for family history or other risk factors per oncologist-recommended interval.
• Breast cancer: standard mammography screening per age and risk; CA 15-3 (CPT 86300) in active treatment context per oncologist.
• Colorectal cancer: standard colonoscopy screening per age-based recommendations; CEA (CPT 82378) for family history or other risk factors per oncologist or GI specialist guidance. No current recommendation to use semaglutide for colorectal cancer prevention.
• Gallbladder cancer: RUQ symptom-prompted ultrasound; not routine screening.

Discontinuation triggers. New cancer diagnosis on therapy → oncology co-management decides protocol continuation. Active malignancy was generally excluded from registration trials; clinician judgment with oncology consultation.

6.8 Injection-site AE class

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, nodule) in approximately 5% of patients on weekly subcutaneous semaglutide; usually mild and self-resolving. Lipohypertrophy can develop with site-rotation failure.

Identification. Patient-reported or visit-observed. Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly). Topical hydrocortisone for pruritus. Discontinuation rarely indicated for injection-site AE alone.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a labeled contraindication (§2.4) → permanent discontinuation.

6.9 Hypoglycemia AE class (T2D indication with concurrent insulin or sulfonylurea)

Anticipatory framing. GLP-1 RA monotherapy is not a hypoglycemia-inducing class — the glucose-dependent insulin-secretion mechanism is protective against hypoglycemia in the absence of concurrent hypoglycemia-inducing agents. Hypoglycemia risk emerges when GLP-1 RA is combined with insulin or sulfonylurea. Pivotal-trial protocol: reduce the dose of the concurrent agent at GLP-1 RA initiation (insulin typically reduced ~20% at semaglutide initiation; sulfonylurea typically reduced ~50% or discontinued).

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target.

First-line management. Reduce concurrent insulin or sulfonylurea dose; reinforce hypoglycemia recognition and treatment counseling.

Discontinuation triggers. Hypoglycemia from semaglutide is not a discontinuation indication for semaglutide; it is a dose-adjustment indication for the concurrent agent.

6.10 Dysesthesia AE class (Wegovy HD 7.2 mg specific)

Anticipatory framing. Dysesthesia is the defining new AE of the 7.2 mg dose — 22.9% of 7.2 mg participants vs 0.5% of placebo in STEP UP non-T2D (PMID 40961952); 18.9% vs 4.9% in STEP UP T2D (PMID 40961953). Mechanism not fully characterized but does not appear to indicate progressive nerve damage; reversible with dose reduction.

Identification. Patient-reported altered skin sensation (tingling, burning, numbness).

First-line management. Counsel patients explicitly about altered skin sensation; document baseline neurologic exam before 7.2 mg escalation; plan dose reduction or discontinuation if dysesthesia is severe or persistent. Patient counseling: “About 1 in 4 people on the higher dose get tingling or burning sensations. It’s not nerve damage — it’s a known side effect that resolves with dose reduction.”

Discontinuation triggers. Severe or persistent dysesthesia → dose-down to Wegovy 2.4 mg; if not tolerable at 2.4 mg either, transition to alternative.

6.11 Drug-drug interaction class

Concurrent agents requiring dose-adjustment or absorption-monitoring:

• Insulin / sulfonylureas: see §6.9; dose-reduce concurrent agent at semaglutide initiation.
• Warfarin (narrow therapeutic window + gastric emptying delay): closer INR monitoring during titration and dose changes.
• Levothyroxine (gastric emptying delay): thyroid function monitoring with levothyroxine; closer if symptoms.
• Oral contraceptives (gastric emptying delay): backup contraception counseling during initiation period.
• Proton pump inhibitors (oral semaglutide / Rybelsus only): PIONEER program absorption-context counseling; concurrent PPI may affect Rybelsus absorption.
• DPP-4 inhibitors: mechanism-redundant; combination not indicated (no additive benefit; redundant DPP-4 inhibition prolongs endogenous GLP-1 while semaglutide is exogenous DPP-4-resistant analog).
• Other GLP-1 RAs: mechanism-redundant; not indicated.
• Tirzepatide: overlapping GLP-1R agonism; not indicated as combination — transition between agents, not co-administration.
• SGLT-2 inhibitors: complementary; commonly co-prescribed in T2D + CVD/CKD where outcome benefits stack (§9.2).
• Metformin: complementary; standard combination in T2D management.
• Concomitant peptide therapeutics (BPC-157, GHK-Cu, other peptides): case-by-case, no specific contraindication established but cumulative immunogenic load considered.

6.12 Cardiovascular safety summary

CV safety profile favorable across SUSTAIN-6 (PMID 27633186), SELECT (PMID 37952131), SOUL (PMID 40162642), and STEP-HFpEF program. No signal for myocardial infarction, stroke, or CV mortality elevation; demonstrable reduction in MACE in established CVD populations.

Heart rate elevation: mean 1–4 bpm increase across registration trials. Clinical significance limited at population level; case-by-case evaluation in patients with arrhythmia or significant tachycardia at baseline.

Blood pressure: modest reduction (3–5 mm Hg systolic, 1–3 mm Hg diastolic) through weight-loss-mediated and possibly direct vascular mechanisms.

6.13 Pregnancy and lactation considerations (cross-reference §8.4 + verbatim Anchor 3 in §10.4)

Brief operational summary; verbatim research-state-leading framing is in §10.4. Discontinue upon pregnancy awareness. For planned pregnancies: ≥2-month washout before conception attempts. Counsel reproductive-age patients on contraception during treatment. Lactation-exposure data is research-state-incomplete; semaglutide is not used during breastfeeding per current Novo Nordisk product labels.

6.14 Worked AE management scenarios

Scenario A — Maintenance-dose moderate-severity nausea. A non-diabetic adult on Wegovy 2.4 mg, Month 6 on target dose, persistent moderate nausea (Grade 2, recurring 2–3 days after each weekly injection), early satiety, 12 kg total weight loss (~11% of starting weight, on-trajectory for STEP-1 effect-size).

Protocol response.First-line: meal-size and composition reinforcement; scheduled (not just PRN) ondansetron for the 2–3-day post-injection window. Reassessment at Month 7 visit: if nausea remains Grade 2 and patient is on-trajectory for indication target, continue current dose; if Grade 2 nausea is unacceptable to patient, dose-down to 1.7 mg with Month 9 weight-trajectory reassessment.

Scenario B — Confirmed acute pancreatitis on Ozempic 1.0 mg. A T2D adult on Ozempic 1.0 mg, Month 4, presents with acute severe upper abdominal pain radiating to back, vomiting, hospitalized in ED. Lipase elevated to 5× upper limit normal; abdominal CT shows mild peripancreatic fat stranding without necrosis. Triglycerides 220 mg/dL (not severely elevated). No gallstones on imaging. No alcohol history.

Protocol response. Confirmed acute pancreatitis; alternative etiologies ruled out — semaglutide-attributable pancreatitis is the working diagnosis. Discontinue Ozempic. Supportive pancreatitis management per standard-of-care. Permanent discontinuation post-recovery; transition to non-GLP-1 T2D regimen — consider sitagliptin versus pioglitazone or SGLT2 inhibitor; counsel on T2D-progression context.

Scenario C — Confirmed NAION on Wegovy 2.4 mg. A non-diabetic adult on Wegovy 2.4 mg, Month 4, develops acute painless monocular vision loss in left eye over ~24 hours. Ophthalmology urgent evaluation confirms left optic disc edema with altitudinal visual field defect; ESR and CRP normal (excluding GCA). Diagnosis: NAION, left eye.

Protocol response. Discontinue Wegovy. Confirmed NAION → permanent semaglutide discontinuation. Ophthalmology co-management for fellow-eye monitoring (post-NAION fellow-eye recurrence is the established counseling beat). The patient and clinician decide whether to attempt an alternative GLP-1 RA or transition to non-GLP-1 approach.

Scenario D — Dysesthesia on Wegovy HD 7.2 mg. A 56-year-old male on Wegovy HD 7.2 mg, Month 2 at the higher dose, reports new bilateral feet tingling and intermittent burning sensation. Baseline neurologic exam pre-7.2 mg escalation was normal. No other risk factors for peripheral neuropathy (HbA1c 5.8, no diabetes; B12 normal; no alcohol).

Protocol response. Anticipatory framing: dysesthesia in 22.9% of 7.2 mg STEP UP participants; reversible with dose reduction; not progressive nerve damage. Counsel patient per canonical §12.10 Pattern 9. First-line: continue 7.2 mg for 2 more weeks with patient-reported symptom trajectory; if intensifying or unacceptable, dose-down to Wegovy 2.4 mg. If dysesthesia persists at 2.4 mg, transition to alternative.

“Pancreatitis-attributable to semaglutide” is precise (alternative etiologies ruled out, temporal association); the labeled framing for semaglutide pancreatitis is “labeled cautionary use,” not “labeled contraindication” — but post-event, permanent discontinuation is the clinical-judgment standard. “NAION signal” is precise — post-marketing pharmacovigilance + EMA-labeled “very rare” June 2025; FDA has not updated US labels as of 2026-05-13; management response (discontinuation) is clinician-judgment alignment with signal-direction precaution, not labeled US mandate.

---

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when semaglutide’s primary effect has not met its target (non-response) or has stalled below a clinically meaningful endpoint (plateau). §7 is the diagnostic-and-decision branch point: distinguish pseudo-plateau (apparent stall that is normal-trajectory variation) from true plateau (legitimate response stall requiring intervention) from non-response (insufficient initial effect from the start).

is — before the decision branches and the transition options. Opening with “transition to tirzepatide” would steer clinicians away from semaglutide before the diagnostic work is done.

7.2 Pseudo-plateau vs true plateau vs non-response

Pseudo-plateau. Apparent stall in weight or HbA1c that is in fact within normal week-to-week or month-to-month variation, or that reflects body-composition change (lean mass preservation with continued fat-mass loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern. STEP-1 and most weight-loss molecules show a deceleration in Months 6–9 even on continued effective therapy. Pseudo-plateau is recognized by trajectory-context — comparing the patient’s curve to the STEP-1-typical curve.

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. Recognized by trajectory inflection plus an adequate observation window (typically 2–3 months at stable dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3–6 on target dose with effect substantially below trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing

Weight-regulation physiology operates on a defended set-point that the body actively resists changes from. Weight loss into a new set-point window typically requires sustained pharmacologic and behavioral intervention; loss beyond the body’s defended range tends to recruit counter-regulatory responses (increased hunger signals, decreased energy expenditure — adaptive thermogenesis).

True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. The protocol framing in counseling (§10) does not pathologize plateau but reframes it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

STEP-4 (PMID 33755728) and STEP-1 Extension (PMID 35441470) demonstrate two-thirds weight regain within 12 months of discontinuation — the set-point defense mechanism re-establishes a higher equilibrium once pharmacologic support is withdrawn. SELECT 4-year (PMID 38740993) demonstrates sustained benefit with continued therapy. The biology of weight regulation, not patient willpower, governs maintenance trajectory.

7.4 Decision tree for plateau / non-response

1. Confirm adherence. Missed doses, injection-technique issues, oral-formulation absorption issues (PIONEER program SNAC discipline — empty stomach, ≤120 mL water, 30-minute pre-food window) are the most common pseudo-non-response causes. Confirm via patient interview and prescription-refill audit.

2. Confirm trajectory-context. Plot the patient’s curve against the STEP-1 trajectory marker (≥5% Week 16–20; ≥10% Week 32–40; ≥15% Week 52–68 for CWM) or against SUSTAIN HbA1c trajectory for T2D. If on-trajectory, pseudo-plateau — continue current dose, reassess at next interval.

3. Confirm dose attainment. Is the patient on target dose? If not, complete titration to target dose; reassess at Month 3 on target.

4. Reassess phenotype. Does the patient’s clinical picture support a phenotype the STEP / SUSTAIN program enrolled, or is the patient in an under-represented or out-of-trial phenotype (LADA misclassified as T2D; lean BMI <27 without comorbidity; advanced beta-cell-failure T2D)? for under-represented phenotypes, expected effect-size may be smaller, recalibrate target.

5. If true plateau / non-response confirmed at adequate observation window:

   • CWM context — Wegovy 2.4 mg non-response (<5% weight loss at Month 6 on adherent 2.4 mg):

     • 5a — Wegovy HD 7.2 mg escalation. If patient has tolerated 2.4 mg ≥4 weeks, label-permitted escalation. STEP UP (PMID 40961952) demonstrates –18.7% body weight; 31.2% achieved ≥25% loss. Dysesthesia counseling per §6.10.
     • 5b — Transition to tirzepatide. SURMOUNT-1 effect-size ~22.5% at 15 mg in non-diabetic obesity; SURMOUNT-5 head-to-head (PMID 40353578) –20.2% tirzepatide vs –13.7% semaglutide at max-tolerated doses.
     • 5c — Combination with cagrilintide. CagriSema (cagrilintide + semaglutide) Phase 3 REDEFINE-1 (PMID 40544433): –20.4% body weight (treatment-policy) vs –3.0% placebo; 22.7% at full adherence.
     • 5d — Intensification of behavioral / nutritional / activity program.For some patients, intensification before molecule transition is appropriate.
     • 5e — Retatrutide / orforglipron / aleniglipron pending approval. TRIUMPH-4 –28.7% (Lilly investor disclosure Dec 2025; peer-reviewed publication pending); ACHIEVE / ATTAIN orforglipron program data; ACCESS II aleniglipron Phase 2. Not yet FDA-approved — informational future-state for patient counseling, not current operational option.

   • T2D context — Ozempic 1.0 mg or 2.0 mg HbA1c above-target on adherent maintenance:

     • Transition to tirzepatide.
     • Add SGLT2 inhibitor per ADA/EASD T2D-progression algorithm.
     • Add insulin per ADA/EASD progression algorithm.

   • MASH context — ESSENCE non-response or progression:

     • ESSENCE-anchored semaglutide is the first FDA-approved MASH therapy as of 2026-05-13 (August 2025 approval); non-response transition options are limited.
     • Resmetirom (Rezdiffra, FDA-approved March 2024 — first MASH therapy) is the alternative-class option; thyroid hormone receptor-β agonist.
     • Adjunct considerations: vitamin E (non-diabetic MASH context), pioglitazone (non-diabetic MASH context). Hepatology co-management.

   • CKD context — FLOW non-response:

     • FLOW primary endpoint is composite event reduction, not surrogate-marker improvement; “non-response” is typically not applicable at the individual-patient level over short observation windows.
     • eGFR slope improvement and UACR reduction are the assessable individual-level surrogates (§5.5).
     • Co-management considerations: SGLT2 inhibitor (DAPA-CKD / EMPA-KIDNEY); finerenone if RAS-blockade maximized with residual albuminuria.

   • CV-risk context — SUSTAIN-6 / SELECT non-response:

     • Similar to CKD — CVOT indication is event-reduction, not surrogate; individual-patient “non-response” framing is less applicable.
     • Continued therapy if tolerated; comparator-class transition only if compelling secondary reason (weight, HbA1c, AE profile).

   • PAD context — STRIDE non-response:

     • Walking-distance trajectory is the assessable individual-level outcome.
     • Standard PAD management (vascular surgery referral, structured exercise program, antiplatelet, statin) continues regardless of GLP-1 RA response.

7.5 Worked non-responder scenarios

Scenario A — CWM non-responder, transition decision. A 52-year-old female, non-diabetic, BMI 33 at baseline, on Wegovy 2.4 mg, Month 6 on target dose, has lost 3.2 kg from baseline (~3% of starting weight) — below the STEP-1 effect-size anchor of ~14.9% and below the 5%-at-Month-6 trajectory marker.

Algorithm walkthrough. Step 1 — adherence: patient reports 100% adherence; refill audit confirms no gaps. Adherence-confirmed pseudo-non-response ruled out. Step 2 — trajectory-context: patient’s curve at Month 6 (3% loss) is below STEP-1 25th percentile trajectory (~7% loss). Not on-trajectory. Step 3 — dose attainment: on 2.4 mg target dose; no further titration within Wegovy standard label without 7.2 mg escalation consideration. Step 4 — phenotype reassessment: 52-year-old female, BMI 33, no T2D, prior weight-loss attempts including 18 months on phentermine with regain to current weight — within STEP-1 enrollment phenotype (BMI ≥30, no T2D); prior weight-loss-failure with regain is the typical STEP-1 enrollment phenotype. Phenotype is trial-enrolled; effect-size expectation per STEP-1 is ~14.9%; patient’s response is below typical STEP-1 trajectory. Step 5 — non-response confirmed; decision branches present.

Decision-branch options presented: (5a) Wegovy HD 7.2 mg escalation per STEP UP — possible since patient tolerated 2.4 mg ≥4 weeks; dysesthesia counseling required. (5b) Transition to tirzepatide per SURMOUNT-5 head-to-head higher-effect data. (5c) Add cagrilintide via CagriSema if available per local regulatory status. (5d) IBT intensification per STEP-3 effect-additivity data.

The decision among 5a/5b/5c/5d is patient-anchored, not clinician-mandated. Counseling beats (§10.5 / §10.6) frame the options without steering — present the trial-program-anchored effect-size estimates for each option, present the trade-offs (cost, AE-profile, adherence-complexity, regulatory-availability), and the clinician-patient decision is patient-preference-driven within the medically reasonable options.

Scenario B — T2D HbA1c non-responder. A 61-year-old male, T2D + obesity, on Ozempic 1.0 mg from SUSTAIN-6 CV indication, HbA1c at Month 6: 7.8 (above individualized target 7.0). Weight –6 kg from baseline. Adherence confirmed. No hypoglycemia events on concurrent metformin.

Algorithm walkthrough. Adherence and trajectory confirmed inadequate. Dose attainment: at 1.0 mg — escalation to 2.0 mg label-permitted per SUSTAIN-FORTE. Plan: escalate to 2.0 mg; reassess HbA1c at Month 9. If HbA1c remains above target at 2.0 mg at Month 9: §7 step 5b transition to tirzepatide consideration per SURPASS-2 head-to-head data, OR add SGLT2 inhibitor per ADA/EASD progression algorithm.

Scenario C — Pseudo-plateau identification. A 38-year-old female, non-diabetic, BMI 36 at baseline, on Wegovy 2.4 mg, Month 9 on target dose, weight unchanged at Month 8 and Month 9 (had lost 12 kg cumulatively by Month 7). DEXA shows lean-mass stable, fat-mass continued decline 1.5 kg between Month 7 and Month 9 (waist circumference –3 cm in same interval).

Algorithm walkthrough. Step 1 — adherence confirmed. Step 2 — trajectory-context: cumulative loss at Month 9 (~12% of starting weight) is on-trajectory for STEP-1 50th percentile at Month 9; weight-stability with body-composition shift (fat-mass continuing to decline) is pseudo-plateau, not true plateau. Reassessment at Month 12 expected to show continued slow weight decline as fat-mass conversion completes.

Counseling beat — pseudo-plateau is biology-as-expected, not failure. “Your weight has stabilized but your body composition is still changing — you’re continuing to lose fat mass while preserving muscle. That’s actually the ideal trajectory.”

8. Discontinuation and tapering

8.1 Purpose

Define when to stop semaglutide, how to taper if tapering is indicated, and how to frame post-discontinuation expectations — particularly the weight-regain trajectory in CWM indications. §8 is the symmetric counterpart to §4 (initiation): just as initiation has anticipatory framing for AE and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate.

legitimate clinical pathway (patient-preference, indication-resolution, AE-driven, pre-conception planning) before discussing weight-regain trajectory. The two-thirds-regain finding is presented in §8.5 as biological expectation, not as therapeutic failure.

8.2 Discontinuation triggers

Discontinuation is indicated when one of the following emerges:

• Confirmed contraindication discovery (new MTC diagnosis, new MEN-2 family-history identification, new pregnancy in CWM indication). §2.4 hard contraindications are immediate-discontinuation triggers.
• Severe AE attributable to semaglutide — confirmed acute pancreatitis (§6.3), confirmed NAION (§6.6), severe hypersensitivity reaction (§6.8). §6 AE-class-specific discontinuation triggers.
• Indication remission or resolution — T2D HbA1c sustained below target with weight stable in some patients (rare in CWM context); MASH histologic resolution sustained.
• Patient preference. Patient-anchored discontinuation decision is legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway, not to override the patient’s decision.
• Cost / access barriers. A documented practice-level reality, particularly for non-T2D Wegovy indication where insurance coverage is more variable.
• Pre-conception planning for reproductive-age patients on CWM indication: discontinuation with ~35-day pharmacokinetic washout + 8-week label window per §8.4 arithmetic. This is anticipatory discontinuation, not reactive. Verbatim Anchor 3 framing in §10.4.
• Pregnancy occurring on protocol. Labeled contraindication for CWM indications. Immediate discontinuation; obstetrics co-management.

8.3 How to taper — clinician-judgment within label

For GLP-1 RAs in CWM indication, pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven pharmacokinetic washout occurs at fixed kinetics regardless of taper schedule. However, gradual dose reduction

1. Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation (the patient’s reduced appetite signal returns gradually, allowing meal-size and meal-composition adaptation in parallel).
2. AE-class symmetry.

Typical taper pattern — semaglutide CWM (clinician-judgment within label):

• 2.4 mg → 1.7 mg for 4 weeks
• 1.7 mg → 1.0 mg for 4 weeks
• 1.0 mg → 0.5 mg for 4 weeks
• Discontinue

Total taper period: ~12 weeks. clinician-judgment within label, not label-mandated; the FDA label permits abrupt discontinuation.

Wegovy HD 7.2 mg taper. Step down through 2.4 mg first (Wegovy HD → Wegovy standard); then apply CWM taper schedule.

Ozempic / Rybelsus taper (T2D). Less commonly tapered; T2D maintenance is typically continued indefinitely. If discontinuing, gradual step-down per analogous pattern (1.0 mg → 0.5 mg × 4 weeks → 0.25 mg × 4 weeks → off, for Ozempic).

Confirmed AE-attributable discontinuation (pancreatitis, NAION, severe hypersensitivity) — no taper; abrupt discontinuation appropriate given the AE-attributable etiology.

8.4 Pre-conception washout arithmetic — semaglutide

Semaglutide has an elimination half-life of approximately 1 week. Approximately 5 half-lives are required for >95% pharmacokinetic clearance — approximately 5 weeks, i.e., approximately 35 days.

The FDA label for Wegovy and Ozempic specifies discontinuation at least 2 months (≥8 weeks) before a planned pregnancy. The 35-day arithmetic is the pharmacokinetic minimum; the 8-week label recommendation is the conservative clinical recommendation accounting for pharmacokinetic and pharmacodynamic clearance plus a margin.

The 8-week pre-conception window is the operational counseling beat for reproductive-age patients on semaglutide CWM indication — §10.4 counseling beats anchor to this arithmetic with verbatim Anchor 3 precision.

PCOS-context fertility considerations. Metformin + semaglutide combination in PCOS produced greater weight loss, testosterone reduction, and natural pregnancy rate (35% vs 15% metformin alone). For PCOS patients on semaglutide who become more fertile and are planning conception, pregnancy-attempt timing requires integration with the ≥2-month washout: discontinue semaglutide → ≥2-month washout → conception attempts. This is a different clinical scenario from contraception-failure unplanned pregnancy and warrants pre-treatment counseling for reproductive-age PCOS patients.

8.5 Post-discontinuation weight-regain framing

Trial-program data on post-semaglutide-discontinuation weight regain:

• STEP-4 (Rubino 2021 JAMA, PMID 33755728) randomized withdrawal: two-thirds of run-in weight loss regained within 48 weeks of switch to placebo
• STEP-1 Extension (Wilding 2022, PMID 35441470) 1-year off-treatment: two-thirds of weight loss regained within 52 weeks
• Cardiometabolic improvements reverse in parallel with weight regain

The mechanism — set-point physiology and the defended-weight biology described in §7.3 — predicts that without pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium.

The protocol framing in counseling (§10.7) does not pathologize weight regain post-discontinuation; it frames the regain trajectory as the expected biological response, the same way pre-treatment counseling framed the appetite-suppression mechanism as the biological intervention. Patients considering discontinuation are counseled on the expected regain trajectory and on the re-initiation pathway if regain occurs and warrants re-treatment.

Counterpoint framing: “Obesity is a chronic relapsing condition. Semaglutide isn’t a course you complete; it’s a chronic therapy like blood pressure medication.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation: typically re-titration from the starting dose is the protocol-recommended pattern — the tolerability re-priming is equivalent to initial titration; abrupt re-initiation at the prior target dose is not recommended due to GI AE recurrence risk.

§4 titration applies. Indication confirmation per §1, selection-criteria re-screening per §2, and pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

Re-initiation tolerability research direction. Whether prior exposure alters re-titration tolerability is research-state-incomplete; clinical practice defaults to full re-titration discipline.

8.7 Discontinuation scenarios

Scenario A — Pre-conception planning. A 32-year-old female on Wegovy 2.4 mg, Month 14 on target dose, has lost 16.8 kg (~17% of starting weight, on-trajectory) and is planning conception in approximately 6 months.

Counseling beat (verbatim Anchor 3 framing in §10.4). Discuss the 8-week pre-conception window per label; plan taper start approximately 5 months from now (12-week taper period, then ~8-week post-discontinuation pharmacokinetic-and-margin window per label). The counseling presents the pharmacokinetic facts (1-week half-life, 35-day pharmacokinetic clearance, 8-week label recommendation), the Parker 2025 (PMID 40329607) human pregnancy-exposure research-state data (LEADS the conversation per verbatim Anchor 3), and the post-discontinuation weight-regain trajectory without steering toward continuation or discontinuation; the patient’s reproductive-planning decision is patient-anchored.

Scenario B — Patient-preference discontinuation at Month 18. A 58-year-old male on Wegovy 2.4 mg, has lost 14.5 kg (~15% of starting weight) and stabilized at the new weight for the last 4 months; reports tolerable but consistent mild GI AE profile and wishes to discontinue.

Counseling beat. Discuss STEP-4 / STEP-1-extension trajectory data — approximately two-thirds of lost weight is typically regained by 12 months post-discontinuation; re-initiation pathway is available if regain occurs and is clinically meaningful. Protocol taper: 2.4 mg → 1.7 mg × 4 weeks → 1.0 mg × 4 weeks → 0.5 mg × 4 weeks → off. Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP; re-initiation decision at any monitoring visit if regain warrants and patient agrees.

Scenario C — Confirmed acute pancreatitis (§6.3 case). Permanent discontinuation. No taper — abrupt discontinuation appropriate given the AE-attributable etiology. Transition to non-GLP-1 alternative per indication.

Scenario D — Confirmed NAION (§6.6 case). Permanent discontinuation regardless of indication continuation. No taper. Module 5 indication continuation decision per §6.6 (alternative GLP-1 RA tirzepatide is not contraindicated on NAION grounds per class-differentiation; patient-clinician decision).

Scenario E — New pregnancy on protocol. A 29-year-old female on Wegovy 2.4 mg discovers pregnancy at ~6 weeks gestation. CWM-indication semaglutide is a labeled contraindication in pregnancy. Immediate discontinuation. Obstetrics co-management; the pharmacokinetic clearance window (~35 days, with first-trimester exposure already occurred) is documented for the obstetrics record. Counsel patient on Parker 2025 (PMID 40329607) human pregnancy-exposure data: incidence of congenital abnormalities appears relatively low in the pooled dataset of unplanned-pregnancy contexts; sample size is limited. Post-pregnancy and post-lactation, re-initiation decision per §1 indication and §2 selection-criteria reapplication.

Scenario F — Cost / access discontinuation. A patient on Wegovy 2.4 mg loses insurance coverage; out-of-pocket cost is unsustainable. Counseling beat per verbatim Anchor 2 framing in §10.3: compounded semaglutide is a real-world clinical option used by many patients; let’s review specific compounding pharmacy quality practices, walk through reconstitution training, and discuss whether transition to compounded vs continued FDA-approved (with patient-assistance program inquiry) vs alternative-class consideration fits the patient’s situation. The decision is patient-anchored within the factual landscape.

Scenario G — Pre-procedural / peri-surgical hold. A patient on Wegovy 2.4 mg scheduled for elective surgery requiring general anesthesia. Anesthesia / surgical-team consultation per current pre-procedural GLP-1 RA guidance (residual gastric contents risk; hold semaglutide pre-procedure per local protocol — typically 1 week for weekly SC formulations). Resume post-procedure once oral intake and GI motility have normalized; usually does not require full re-titration if hold is brief (1–2 doses).

9. Combination rules

9.1 Purpose

Define what stacks with semaglutide, what is contraindicated in combination, and the rationale for each combination category. §9 is the protocol’s bridge to Module 5.12 Combination Protocols and to the lean-mass-stack protocols (M5.5 Tesamorelin / AOD-9604; M5.6 Lean Mass / CJC-Ipamorelin / MOTS-c).

The section is structured by combination class: within-Module-5 combinations (GLP-1 RA + amylin analog; GLP-1 RA + SGLT2; GLP-1 RA + insulin; GLP-1 RA + DPP-4 not indicated; intra-GLP-1-RA-class transitions not co-administration), cross-Module combinations (lean-mass stacks; visceral-adiposity stacks; skin/connective-tissue peptides), and contraindicated combinations.

Every combination in this section is reconciled with §2 (a combination cannot include an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10.

9.2 Within-Module-5 combinations

Semaglutide + cagrilintide (CagriSema; Novo Nordisk fixed-combination). Mechanism rationale: amylin co-released with insulin in physiologic glucose response; cagrilintide (long-acting amylin receptor agonist) modulates gastric emptying and central satiety via brainstem amylin pathway in a mechanism complementary to GLP-1. REDEFINE-1 Phase 3 (PMID 40544433; n=3,417; 68 weeks; obesity without diabetes): –20.4% body weight (treatment-policy estimand) vs –3.0% placebo (–17.3 pp difference); 22.7% body weight loss at full adherence vs 16.1% semaglutide alone, 11.8% cagrilintide alone. 60% achieved ≥20% weight loss; 23% achieved ≥30%. REDEFINE-2 in obesity + T2D (PMID 40544432; n=1,206): cagrilintide-semaglutide –13.7% body weight vs –3.4% placebo; 73.5% reached HbA1c ≤6.5% vs 15.9% placebo. regulatory status as of 2026-05-13 is Phase 3 readout reported; FDA submission status — check current per Bibliography. CagriSema is not yet FDA-approved as of 2026-05-13. Effect-size anchor positions CagriSema between semaglutide alone and tirzepatide for non-diabetic obesity efficacy. Mechanism rationale: amylin receptor agonism + GLP-1R agonism → additive weight-loss magnitude.

Semaglutide + GIP agonism (tirzepatide — not a combination per se). Tirzepatide is a single-molecule dual GLP-1/GIP agonist; cross-class transition from semaglutide to tirzepatide is operationally a §7 non-response algorithm consideration, not a co-administration. Concurrent semaglutide + tirzepatide is not indicated (overlapping GLP-1R agonism; additive AE profile; no demonstrated additive benefit) — transition between agents per §7 / §8 transition pattern.

Semaglutide + GIP + glucagon (retatrutide — not a combination per se). Retatrutide is a single-molecule triple-receptor agonist; not co-administered with semaglutide.

Semaglutide + SGLT2 inhibitor (T2D indication context). Class-additive HbA1c and cardiovascular / kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context. Mechanism rationale: SGLT2 inhibitor adds glucose-osmotic-diuretic and ketogenesis-modulating effects; the combination is broadly supported by individual-agent CVOT (EMPEROR, DECLARE, DAPA-HF, EMPA-REG) and KOOT (DAPA-CKD, EMPA-KIDNEY) data and by clinical-practice cohort analyses. combination is effect-additive on HbA1c, on kidney composite, and on CV events per individual-agent data; cross-class combination supported by individual-agent trial data, not by head-to-head combination RCT.

Semaglutide + insulin (T2D advanced). Common in T2D with progressed beta-cell failure where GLP-1 RA monotherapy is insufficient. §6.9 hypoglycemia management applies; concurrent insulin dose typically reduced ~20% at GLP-1 RA initiation. IcoSema (Novo Nordisk; insulin icodec + semaglutide; once-weekly basal insulin + once-weekly GLP-1 RA combination) — EMA CHMP positive opinion 2025 (Kyinsu / IcoSema); FDA status check current. Mechanism rationale: once-weekly basal insulin replacement + once-weekly GLP-1 RA for T2D with reduced injection burden.

Semaglutide + metformin (T2D foundational). Standard combination in T2D management; complementary mechanism (metformin hepatic glucose production suppression + GLP-1 RA insulin-secretion / appetite). Foundational T2D regimen.

Semaglutide + DPP-4 inhibitor — not indicated. Mechanistic overlap (DPP-4 inhibitor preserves endogenous GLP-1; redundant with exogenous DPP-4-resistant analog semaglutide). No additive HbA1c benefit. Avoid co-prescribing.

Semaglutide + GLP-1 RA (within-class, e.g., liraglutide concurrent) — not indicated. Mechanism-redundant.

9.3 Cross-Module combinations — lean-mass and body-composition stacks

Cross-Module combinations involve adding a peptide outside the GLP-1 RA / amylin / GIP / glucagon metabolic-axis family to address a complementary clinical objective — most commonly lean-mass preservation during weight loss.

Semaglutide + CJC-1295 / Ipamorelin (GH secretagogue stack; M5.6 Lean Mass canon). Mechanism rationale: CJC-1295 (GHRH analog) plus Ipamorelin (GH secretagogue) elevates endogenous growth hormone pulsatility, supporting lean-mass preservation during caloric deficit. Module 5.6 Lean Mass canon documents the M5.6 v3 stack with phenotype targeting, monitoring (IGF-1 anchored), and AE-class considerations. CJC-1295 and Ipamorelin are not FDA-approved for lean-mass preservation in CWM context; this is clinician-judgment within informed-consent and primary-source-supported clinical reasoning (mechanism rationale + M5.6 v3 clinical-practice cohort, not Phase 3 RCT for the indication). CJC-1295 and Ipamorelin are peptides — Peptides folder path.

Semaglutide + MOTS-c (mitochondrial peptide). Mechanism rationale: MOTS-c is a mitochondrially-encoded peptide with metabolic-regulator activity in preclinical models. Trial-program status: limited human Phase 1/2 data.

Semaglutide + Tesamorelin (FDA-approved for HIV-associated lipodystrophy; off-label for visceral adiposity in non-HIV context). Mechanism rationale: Tesamorelin (GHRH analog) reduces visceral adipose tissue; in combination with GLP-1 RA-mediated weight loss, visceral-adiposity-targeted effects are additive. Module 5.5 Tesamorelin canon documents trial-program data and off-label clinical use. off-label-for-non-HIV-visceral-adiposity framing is explicit. Off-label use is clinician-judgment within informed-consent and primary-source-supported clinical reasoning.

Semaglutide + GHK-Cu (skin / connective-tissue peptide). Cross-Module — GHK-Cu is a Module 5.7 (skin-elasticity, post-weight-loss skin tone) topical or injectable application. GHK-Cu trial-program data are limited for the post-weight-loss-skin indication specifically; clinician judgment with patient-anchored expectations.

Semaglutide + AOD-9604 (M5.5 stack adjacent). Mechanism rationale: AOD-9604 is a synthetic fragment of human growth hormone (hGH 177–191) with reported lipolytic activity in preclinical and limited clinical data. Clinical evidence base is limited; investigational status applies. Module 5.5 documents the framework.

9.4 Contraindicated combinations

• Semaglutide + DPP-4 inhibitor (§9.2 — not contraindicated by safety; contraindicated by lack of additive benefit and by clinical-practice convention).
• Concurrent oral semaglutide and injectable semaglutide (avoid; redundant within-molecule).
• Concurrent semaglutide and tirzepatide (avoid; redundant within-class mechanism with additive AE profile and no demonstrated additive benefit; transition between agents, not co-administration).
• Semaglutide + sulfonylurea at full sulfonylurea dose (relative — combination produces excess hypoglycemia risk; sulfonylurea should be reduced or discontinued at semaglutide initiation per §6.9).
• Semaglutide + agents that severely delay gastric emptying (relative — additive gastric-emptying delay may worsen GI AE profile and may impair absorption of concurrent oral medications).
• Semaglutide + concurrent other GLP-1 RA (liraglutide, dulaglutide, exenatide — mechanism-redundant; not indicated).

9.5 Worked combination scenarios

Scenario A — Semaglutide 2.4 mg + CJC-1295 / Ipamorelin stack (M5.6 v3). A 47-year-old male, baseline BMI 36, on Wegovy 2.4 mg, Month 8 on target dose, has lost 16 kg with DEXA showing ~30% of lost mass as lean mass (above the 20–25% typical proportion for unsupplemented weight loss).

Protocol response. Add M5.6 v3 stack — CJC-1295 + Ipamorelin per the M5.6 stack protocol with IGF-1 monitoring and GH-secretagogue-class AE awareness. Monitoring: DEXA at 3 and 6 months on stack to track lean-mass trajectory; IGF-1 quarterly.

“This is an off-label combination. CJC-1295 and Ipamorelin aren’t FDA-approved for lean-mass preservation in weight-loss context; the rationale comes from the growth-hormone-secretagogue mechanism plus our clinical-practice cohort under the M5.6 stack protocol — not Phase 3 RCT data for this specific indication. Here’s what the evidence supports and what it doesn’t, and what monitoring we’d add. Let’s discuss whether this fits your goals.”

Scenario B — Semaglutide + SGLT2 inhibitor (T2D advanced). A 61-year-old male with T2D + CKD eGFR 42, on Ozempic 1.0 mg with HbA1c 7.4 (above individualized target 7.0); add empagliflozin 10 mg daily per ADA/EASD T2D-progression algorithm.

Protocol response. Combination is well-supported by individual-agent CVOT/KOOT data and by additive HbA1c reduction. Monitoring: eGFR at 2 weeks post-SGLT2 initiation (typical small reversible eGFR decline expected), then routine quarterly per §5.

Scenario C — Semaglutide + insulin (T2D advanced with concurrent insulin). A 67-year-old female with T2D for 22 years, on insulin glargine 40 units daily + insulin aspart 8 units pre-meal × 3, HbA1c 7.6, BMI 32. Add Ozempic 0.25 mg weekly per standard initiation; reduce glargine to 32 units (–20%) at Ozempic initiation; closer glucose monitoring; patient counseling on hypoglycemia symptoms.

Protocol response. Standard §6.9 hypoglycemia-prevention discipline. Titrate Ozempic per §4.3; reassess insulin requirements at each titration step and reduce further as HbA1c trends down. Goal: HbA1c reduction to individualized target while reducing insulin burden. IcoSema (insulin icodec + semaglutide) is an emerging once-weekly basal + GLP-1 RA combination option per EMA approval status — check current FDA status.

Scenario D — Semaglutide + tirzepatide concurrent — contraindicated. A patient seeking dual-class metabolic intensification.

Counseling beat. Combination not indicated — these are within-class redundant agents; transition between them (§7 non-response algorithm) is the appropriate decision, not co-administration. Effect-size context: SURPASS-2 head-to-head (PMID 34170647) supports tirzepatide as the higher-effect alternative if semaglutide non-response is the clinical context; transition with appropriate semaglutide discontinuation (per §8 — abrupt acceptable in this transition context given immediate replacement with same-class agent) and tirzepatide initiation per its own initiation protocol.

Scenario E — Semaglutide + Tesamorelin off-label visceral adiposity stack. A 54-year-old male, BMI 32, T2D, on Ozempic 1.0 mg, with persistent central / visceral adiposity (waist circumference 112 cm) and high visceral adipose tissue on DEXA, requests visceral-adiposity-targeted intensification.

Counseling beat (verbatim Anchor 5 framing). “Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Its use for non-HIV visceral adiposity is off-label. The mechanism rationale is that Tesamorelin reduces visceral fat through GHRH-receptor agonism; combined with semaglutide’s overall weight-loss and metabolic effects, visceral-adiposity-targeted effects may be additive. The trial-population evidence base for the non-HIV visceral-adiposity use is limited — it’s clinician-judgment within informed-consent and primary-source-supported clinical reasoning, not Phase 3 RCT for this specific indication. Here’s what the evidence supports and what it doesn’t, and what monitoring we’d add. Let’s discuss whether this fits your goals.”

10. Patient counseling beats

10.1 Purpose

Define the protocol’s patient-counseling content — the conversations the clinician has with the patient at each protocol phase. §10 is the operational anchor for and for ; the counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

. This protocol’s §10 carries the verbatim language for the four conversation patterns where verbatim alignment is load-bearing:

• Anchor 1 — Compounded operational characteristics framing → §10.3 below
• Anchor 2 — Compounded vs FDA-approved patient-counseling beat → §10.3 below
• Anchor 3 — Pregnancy section research-state-leading structure → §10.4 below
• Anchor 4 — Multi-dimensional comparator framing → §10.5 below
• Anchor 5 — Off-label / extrapolation framing → §10.6 below

The meta-principle binding all five anchors: lead with what the option IS, never with what it is not. Open with affirmation, present facts neutrally, close with shared-decision-making invitation.

10.2 Initiation conversation

The initiation conversation occurs at the pre-treatment workup completion / §4 initiation visit. Required counseling beats:

• What semaglutide is. Synthetic GLP-1 receptor agonist, ~7-day half-life, once-weekly subcutaneous injection (or once-daily oral for Rybelsus). Trade names: Ozempic for T2D, Wegovy for chronic weight management, Rybelsus for oral T2D.
• What it does for the patient’s indication. Trial-anchored expected effect-size (§4.9 table). For non-diabetic CWM: STEP-1 anchor ~14.9% weight reduction at 68 weeks. For T2D: SUSTAIN-7 anchor HbA1c reduction ~1.8 percentage points. For CV risk reduction: SELECT 20% MACE reduction in obesity + CVD. For MASH: ESSENCE 62.9% MASH resolution / 36.8% fibrosis improvement at 72 weeks. For CKD-in-T2D: FLOW 24% kidney composite reduction. Anchored to the patient’s specific indication.
• The titration schedule (§4.3). Standard pace 16-week to target dose; slow-titration option (each step extended); the patient is informed the timeline is adjustable to tolerability.
• The AE profile expected at each titration step (§6.2 anticipatory framing). Nausea is anticipated, typically attenuates within 2–4 weeks at stable dose; management strategies non-pharmacologic first (meal-size, slow eating, low-fat composition, hydration), ondansetron PRN second. Reassurance that AE-emergence is not failure but is anticipated.
• The pre-conception planning beat for reproductive-age patients (verbatim Anchor 3 — §10.4 below).
• Cost / access realities (verbatim Anchors 1 + 2 — §10.3 below). Present compounded vs FDA-approved if both are available options; present insurance-coverage realities if known.
• What the patient signals back if any concern emerges. Escalation pathway — symptoms warranting in-person evaluation within 48 hours: severe persistent abdominal pain (assess for pancreatitis), vomiting blood, acute vision change (assess for NAION), signs of severe hypersensitivity, signs of acute cholecystitis.
• The chronic-therapy framing: “Obesity is a chronic relapsing condition. Semaglutide isn’t a course you complete; it’s a chronic therapy like blood pressure medication.
• Cancer-context counseling for MTC/MEN-2 screening result. Personal/family MTC or MEN-2 history is a §2.4 hard contraindication identified at workup; absence of family history is the operational green-light for initiation. The boxed warning rationale (rodent C-cell signal; species-specific) is presented factually if patient asks.
• Comparator-class framing (verbatim Anchor 4 — §10.5 below) if patient asks about tirzepatide / retatrutide / orforglipron alternatives.

10.3 Compounded-vs-FDA-approved counseling — verbatim Anchors 1 + 2

This subsection carries the verbatim canonical language for Anchors 1 + 2.

Anchor 1 — Compounded operational characteristics framing:

Compounded semaglutide is a real-world clinical option used by a substantial patient population. It emerged during the 2022–2024 FDA-declared shortage periods through two regulatory pathways:
– 503A pathway — state-licensed pharmacies compounding to individual prescriptions; oversight via state boards of pharmacy
– 503B pathway — FDA-registered outsourcing facilities compounding for office-stock and patient prescriptions; oversight via FDA cGMP inspection

Operational characteristics of compounded preparations:
– Lyophilized vial format (vs Novo Nordisk’s pre-filled pen format)
– Reconstitution with bacteriostatic water by the patient or clinician at point of use; established protocols include measured-dose drawing technique with 30g insulin syringe
– Storage: lyophilized at −20°C (or per pharmacy specification); reconstituted vial at 2–8°C for 28 days per typical compounding protocols
– Salt form varies by compounding pharmacy (acetate, base); counterion specification per certificate of analysis

Quality criteria clinicians evaluate when selecting a compounding pharmacy:
– Sterility testing per USP <797> (sterile compounding) and <800> (hazardous drugs) standards
– Certificate of analysis per batch (peptide content, purity, residual solvents, endotoxin)
– Cold-chain shipping protocols
– 503A state-licensure verification or 503B FDA registration verification
– Pharmacy reputation and clinical-network referral patterns

Operational differences from FDA-approved Novo Nordisk formulations (factual scope, not deficit framing):
– Manufacturing oversight pathway: 503A/503B compounding regulations vs FDA NDA approval (different regulatory regimes)
– Format: lyophilized vial requiring reconstitution vs pre-filled multi-dose pen ready for use
– Storage: compounded reconstituted at 2–8°C × 28 days vs Novo pen at room temperature × 56 days after first use
– Excipient profile: per compounding pharmacy specification vs Novo proprietary formulation

These are operational and regulatory-pathway differences. Clinical decision-making about compounded vs FDA-approved formulations involves cost, dose flexibility, shortage-period continuity, patient preference, and standard quality-criteria evaluation of the compounding pharmacy.

Anchor 2 — Compounded vs FDA-approved patient-counseling beat:

Pattern 2 — Compounded vs FDA-approved semaglutide questions. Patients asking about cost differential between compounded semaglutide and FDA-approved Wegovy/Ozempic, or about whether compounded is ‘the same drug.’ Fact-based frame: Section 8.3.2 / 8.7 — compounded semaglutide is a real-world clinical option used by a substantial patient population, available through 503A (state-licensed) and 503B (FDA-registered outsourcing) pathways. Operational differences from FDA-approved Novo Nordisk formulations: format (lyophilized vial requiring reconstitution vs pre-filled pen), manufacturing oversight pathway (compounding regulations vs FDA NDA), storage (compounded reconstituted at 2–8°C × 28 days vs Novo pen at room temperature × 56 days after first use), excipient profile per pharmacy specification. Quality varies across compounding pharmacies; standard clinician practice includes selecting pharmacies with documented sterility testing (USP <797>/<800>), per-batch certificates of analysis, cold-chain shipping, and state-licensure or FDA registration verification.

Patient-counseling beat: ‘Compounded semaglutide is a real clinical option used by many patients. The operational differences from Wegovy or Ozempic are real — different format that requires reconstitution, different oversight pathway, different storage. Costs are typically lower, and the patient self-administration is similar to insulin self-injection. If you’re considering it, let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.’

isn’tThe verbatim Anchor 2 above is the corrected calibration; subsequent Module 5 protocols mirror this calibration in compounded-context counseling.

10.4 Pregnancy-planning conversation — verbatim Anchor 3

For reproductive-age patients on CWM-indication semaglutide. The conversation LEADS with human pregnancy-exposure research-state data, not with PK arithmetic or label recommendation — this lead-framing discipline is the core of canonical Anchor 3.

Anchor 3 — Pregnancy section research-state-leading structure:

### 6.8 Pregnancy and lactation considerations

Human pregnancy-exposure data — Parker 2025 (PMID 40329607): pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials (semaglutide, liraglutide, dulaglutide, and class-related compounds). Incidence of congenital abnormalities appears relatively low in this pooled dataset; sample size is limited and the exposures are from unplanned-pregnancy contexts (prospective planned-pregnancy exposure data remains an active research direction; Authors call for prospective pregnancy registries).

Standard clinical practice when pregnancy occurs or is planned:
– Discontinue upon pregnancy awareness (semaglutide elimination half-life ~7 days; ~5 half-lives = ~35 days for substantial clearance)
– For planned pregnancies: plan ≥2-month washout before conception attempts to allow complete clearance
– Counsel reproductive-age patients on contraception during treatment
– Lactation-exposure data is research-state-incomplete; semaglutide is not used during breastfeeding per current Novo Nordisk product labels

Animal data context: Reproductive toxicity studies in animals supported the Category X-equivalent contraindication in pregnancy. Animal data does not always translate to human teratogenicity profile; the Parker 2025 human pooled data shows reassuring early signal but is the load-bearing human evidence as of 2026-05-08.

Operational counseling beats anchored to Anchor 3:

• Lead with Parker 2025 human research-state data. Not “contraindicated in pregnancy”; not “discontinue immediately”; not “Category X.” Lead with: incidence of congenital abnormalities appears relatively low in the pooled regulatory-trial pregnancy exposures; sample size is limited; prospective registries are research-direction priority.
• Then the operational discontinuation arithmetic. Half-life ~7 days; ~35 days for >95% pharmacokinetic clearance; FDA label specifies ≥8 weeks pre-conception. Anticipatory discontinuation for planned conception.
• Then animal data + label contraindication framing as scoped factual context. Category-X-equivalent label rests on animal reproductive toxicity. Animal data does not always translate to human teratogenicity profile. Parker 2025 human data is the load-bearing human evidence.
• Post-discontinuation weight-regain trajectory. STEP-4 / STEP-1 extension data — ~two-thirds of lost weight typically regained by 12 months post-discontinuation.
• Patient-anchored reproductive-planning decision. Some patients plan conception within 1–2 years; some within the next decade; some are not planning conception but want awareness of the protocol-discontinuation arithmetic in case planning changes.
• Re-initiation pathway. Post-pregnancy and post-lactation, re-initiation per §8.6 if indication and selection criteria are met.
• PCOS-context fertility considerations. Chen 2025 RCT (PMID 40713699) metformin + semaglutide combination produced greater weight loss, testosterone reduction, and natural pregnancy rate (35% vs 15% metformin alone). For PCOS patients on semaglutide who become more fertile and are planning conception, pregnancy-attempt timing requires integration with the ≥2-month washout: discontinue semaglutide → ≥2-month washout → conception attempts.

“Contraindicated in pregnancy based on animal data (Category X-equivalent). Discontinue at least 2 months before planned conception due to long half-life. Not recommended during breastfeeding.” — three regulatory-status statements before any research-state data. The verbatim Anchor 3 above leads with Parker 2025 human data, relegating animal-data and label-contraindication framing to scoped factual context after the research-state lead. Subsequent Module 5 protocols mirror this structural ordering.

10.5 Comparator conversation — verbatim Anchor 4

For patients with within-class alternatives (semaglutide vs tirzepatide for CWM or T2D, or vs retatrutide / orforglipron / aleniglipron / CagriSema pending approval status). Canonical Anchor 4 requires multi-dimensional fact presentation across 8+ dimensions

Anchor 4 — Multi-dimensional comparator framing:

Pattern 6 — Tirzepatide comparison framing. Patients asking how tirzepatide compares to semaglutide on weight-loss magnitude. Fact-based frame: Section 7.2 — SURMOUNT-5 direct head-to-head (PMID 40353578; n=751; max-tolerated-dose comparison at week 72): tirzepatide −20.2% vs semaglutide −13.7% — ~6.5 percentage-point difference favoring tirzepatide. Cross-trial comparison (separate trials, indirect): SURMOUNT-1 tirzepatide 15 mg −22.5%; STEP UP semaglutide 7.2 mg −18.7%; no head-to-head Wegovy 7.2 mg vs Zepbound 15 mg trial exists. Beyond weight-loss magnitude, additional fact-based dimensions: cardiovascular outcomes evidence base (SELECT for semaglutide; SURMOUNT-MMO for tirzepatide in progress); MASH approval status (semaglutide approved per ESSENCE; tirzepatide MASH program in development); kidney outcomes evidence base (FLOW for semaglutide; tirzepatide kidney outcomes in development); ophthalmologic class-differentiation finding (NAION signal documented for semaglutide; signal absent for tirzepatide per PMID 40383360); GI tolerability profiles; insurance coverage and cost; injection vs oral platform availability.

Patient-counseling beat: ‘Both compounds are evidence-based weight-management options. SURMOUNT-5 head-to-head showed tirzepatide produced ~6.5 percentage points more weight loss at max-tolerated doses. Beyond that, the compounds differ on cardiovascular and other-outcome evidence bases, side-effect profiles, ophthalmologic-signal differentiation, and access. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.’

Operational dimensions for the comparator conversation:

• Weight-loss magnitude. SURMOUNT-5 direct head-to-head: tirzepatide –20.2% vs semaglutide –13.7%. Cross-trial: SURMOUNT-1 tirzepatide 15 mg –22.5%; STEP UP semaglutide 7.2 mg –18.7%; no head-to-head Wegovy 7.2 mg vs Zepbound 15 mg trial exists as of 2026-05-13.
• T2D glycemic comparison. SURPASS-2 head-to-head T2D (PMID 34170647): tirzepatide 15 mg HbA1c reduction ~2.3 percentage points vs semaglutide 1 mg ~1.9 percentage points at Week 40.
• Cardiovascular outcomes evidence base. SELECT (PMID 37952131) for semaglutide CV-risk-reduction in non-diabetic obesity + CVD; SUSTAIN-6 (PMID 27633186) for semaglutide CV-risk-reduction in T2D + CVD; SOUL (PMID 40162642) for oral semaglutide T2D + ASCVD/CKD. SURMOUNT-MMO for tirzepatide CV outcomes — in progress, readout pending.
• MASH approval status. Semaglutide FDA-approved August 15, 2025 for MASH F2/F3 per ESSENCE (PMID 40305708); tirzepatide MASH program in development; not approved as of 2026-05-13.
• Kidney outcomes evidence base. FLOW (PMID 38785209) for semaglutide kidney-composite reduction in T2D + CKD; tirzepatide kidney outcomes in development.
• Ophthalmologic class-differentiation (NAION). NAION signal documented for semaglutide (Hathaway 2024 PMID 38958939; Grauslund Danish nationwide PMID 39696569; Lakhani 180-country PMID 40383360; Cheng 2026 PMID 41021211); signal absent for tirzepatide per Lakhani 2025 PMID 40383360. This is a class-differentiation finding, not class-wide.
• GI tolerability profile. Both have GI-dominant AE profile; tirzepatide trial-program GI AE incidence is similar-to-modestly-higher than semaglutide; both within-class typical patterns. Wegovy HD 7.2 mg-specific dysesthesia AE (22.9% incidence) is semaglutide-specific.
• Route / platform availability. Semaglutide: SC injection (Wegovy/Ozempic/Wegovy HD) + oral (Rybelsus + oral Wegovy 25 mg approved August 2025). Tirzepatide: SC injection (Zepbound/Mounjaro) only as of 2026-05-13; oral tirzepatide in development.
• Cost and access. Patient-specific; insurance-coverage realities vary by indication and jurisdiction. Compounded semaglutide is a real-world clinical option per §10.3 / Anchor 1+2.
• Pending-approval alternatives. Retatrutide (TRIUMPH program; –28.7% TRIUMPH-4 Lilly investor disclosure December 2025; peer-reviewed publication pending; not yet FDA-approved). Orforglipron (oral non-peptide small-molecule GLP-1R; ACHIEVE / ATTAIN program; submission anticipated 2025–2026). Aleniglipron (oral non-peptide; Phase 2 March 2026 readout 16.3% weight loss; Phase 3 H2 2026). CagriSema (REDEFINE-1 –20.4% / 22.7% adherent; submission status check current).

Operational patient-counseling beat:

‘Both compounds are evidence-based weight-management options. SURMOUNT-5 head-to-head showed tirzepatide produced ~6.5 percentage points more weight loss at max-tolerated doses. Beyond that, the compounds differ on cardiovascular and other-outcome evidence bases, side-effect profiles, ophthalmologic-signal differentiation, and access. Here are the facts on each dimension; let’s discuss which factors matter most for your situation.’

“the choice depends on insurance, side-effect profile, and your specific clinical picture, not just maximum weight-loss number.” — steering patient away from tirzepatide-supremacy framing toward semaglutide. The verbatim Anchor 4 above acknowledges tirzepatide’s weight-magnitude advantage explicitly and presents multi-dimensional facts including dimensions where semaglutide has the evidence-base lead (CV outcomes, MASH approval, kidney outcomes) and dimensions where tirzepatide has the lead (weight magnitude, NAION class-differentiation). Subsequent Module 5 protocols mirror this multi-dimensional presentation; never steer through single-dimension framing.

10.6 Off-label / extrapolation conversation — verbatim Anchor 5

For uses outside FDA-approved indications: semaglutide for HFpEF (investigational, label expansion pending); semaglutide for microdosing in lean / metabolically-healthy populations for “longevity” or metabolic-prevention; CJC-Ipamorelin stack for lean-mass preservation; Tesamorelin off-label for non-HIV visceral adiposity; PCOS use; addiction-biology use (alcohol or tobacco use disorder).

Anchor 5 — Off-label / extrapolation framing:

Pattern 8 — Microdosing for longevity or metabolic health (off-label, beyond trial populations). Patients asking about semaglutide for cardiovascular prevention or ‘longevity’ use outside the BMI ≥27 + established-CVD population studied in registration trials. Fact-based frame: SELECT (PMID 37952131) cardiovascular benefit was demonstrated in n=17,604 adults with BMI ≥27 + established CVD without diabetes; mean MACE reduction HR 0.80 over 39.8 months. STEP program weight-management benefit was demonstrated in adults BMI ≥30 (or ≥27 with weight-related comorbidity). FLOW kidney benefit was demonstrated in T2D + CKD. The trial-population evidence base is what we have; effects in lean / metabolically-healthy populations are research-state-uncharacterized. The patient’s question is asking us to extrapolate beyond the studied population to a population where the benefit-risk profile is not established.

Patient-counseling beat: ‘Here’s what the trials studied and what they showed: SELECT enrolled people with obesity (BMI ≥27) and existing heart disease, and showed 20% MACE reduction. STEP enrolled people with obesity for weight management. FLOW enrolled people with diabetes and kidney disease. Your question is about extrapolating to a different population — lean, no established heart disease, possibly seeking microdose ‘longevity’ use. That extrapolation isn’t tested in trials. The known side-effect profile is GI effects, gallbladder events, pancreatitis signal, NAION signal — those apply whether the patient is in the studied population or not. Whether the cardiovascular / metabolic benefit extrapolates is research-state-incomplete. Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, and what monitoring would matter if you decided to proceed.’

Operational counseling beats anchored to Anchor 5 for other off-label / extrapolation scenarios:

• Explicit off-label framing. “This use is off-label” — stated, not implied.
• Primary-source rationale. Trial data supporting the rationale (e.g., STEP-HFpEF for HFpEF rationale; M5.6 v3 stack data for CJC-Ipamorelin lean-mass-stack rationale; Chen 2025 PMID 40713699 for PCOS use; Hendershot 2025 PMID 39937469 for alcohol use disorder context).
• Trial-population scope as fact. Present the enrolled population — what the trial studied and showed — and identify how the patient’s question relates to that scope.
• Research-state-incompleteness framing for extrapolation. Not “no” — research-state-incomplete. The patient’s question is acknowledged, not dismissed.
• Side-effect profile applies regardless of population. GI effects, gallbladder events, pancreatitis signal, NAION signal — known AE profile applies whether the patient is in the studied population or not.
• Informed-consent acknowledgement. Patient understands the use is off-label / extrapolation and consents to clinician judgment within informed-consent standards.
• Monitoring framework. What monitoring would matter if the patient decides to proceed.
• Re-evaluation if labeled indication emerges. If FDA approval for the indication is subsequently granted, the use transitions from off-label to label-supported; counseling re-anchors at that transition.
• Closes with shared-decision-making invitation. “Let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about your specific situation, and what monitoring would matter if you decided to proceed.”

“Off-label use here doesn’t have evidence backing” — dismissive of the patient’s question, framing trial population as exclusion rather than as evidence base for extrapolation discussion. The verbatim Anchor 5 above acknowledges the question, presents trial-population scope as fact, frames extrapolation as research-state-incompleteness, and closes with shared-decision-making invitation. Subsequent Module 5 protocols mirror this acknowledgment-to-invitation structure.

10.7 Discontinuation conversation

For patient-preference, indication-resolution, or AE-driven discontinuation. Required counseling beats:

• Reason for discontinuation framing. Patient-preference (legitimate; protocol’s role is to inform, not override). Indication-resolution (rare in Module 5; framing is celebratory and prepares for re-initiation if regain). AE-attribution (clinical decision; protocol-mandated where applicable per §6).
• Taper schedule (§8.3). Standard CWM taper: 2.4 mg → 1.7 mg × 4 weeks → 1.0 mg × 4 weeks → 0.5 mg × 4 weeks → off. Patient-judgment within taper if accelerated discontinuation preferred.
• Post-discontinuation weight-regain framing. STEP-4 trajectory data: ~two-thirds of lost weight typically regained by 12 months post-discontinuation. Framed as expected biological response, not pathologized: “Obesity is a chronic relapsing condition. Semaglutide isn’t a course you complete; it’s a chronic therapy like blood pressure medication.
• Re-initiation pathway (§8.6). Available if regain occurs and warrants re-treatment; titration restarts at §4 starting dose, not at prior target dose.
• Pre-conception discontinuation (verbatim Anchor 3 framing — §10.4). Specific 8-week pre-conception arithmetic; research-state-leading Parker 2025 framing.

10.8 Other reusable counseling beats

The following counseling beats are derived from canonical §12.10 (Pattern 1, 3, 4, 5, 7, 9, 10) and are operational reference for the most commonly encountered patient-discourse patterns:

Pattern 1 — Dosing-acceleration counseling. Patient arriving with belief that faster titration produces better results. Patient-counseling beat: “The slow titration isn’t bureaucratic caution; it’s matched to how the drug accumulates in your system.” Anchored in the ~4–5 week steady-state plasma concentration time and the registration-trial GI tolerability rationale.

Pattern 3 — Cancer-fear amplification counseling. Patient arriving with belief that semaglutide causes thyroid or pancreatic cancer based on social-media misreading. Patient-counseling beat: “The black box warning is precautionary based on rat studies. Human data over many years and tens of thousands of patients shows minimal-to-no signal for the cancers people worry about. Your individual cancer-history context matters; let’s address it specifically.” Anchored in canonical §5 framework + 2026 cancer SR PMID 41359966 + §5.2 species-specificity (Bjerre Knudsen PMID 20203154).

Pattern 4 — Stop-when-you-reach-goal counseling. Patient arriving with belief that semaglutide is a “course” to complete and discontinue at goal weight. Patient-counseling beat: “Obesity is a chronic relapsing condition. Semaglutide isn’t a course you complete; it’s a chronic therapy like blood pressure medication.

Pattern 5 — NAION dismissal vs over-fear counseling. Either “the FDA hasn’t put it on the label so it’s not a real risk” (under-reaction) or “I read on Reddit semaglutide will blind people” (over-reaction). Patient-counseling beat: “There’s a real but rare eye-nerve risk. About 1 in 10,000 people per year. We’ll review your eye-risk factors and decide together whether ophthalmology baseline before starting makes sense for you.” Anchored in EMA “very rare” June 2025 classification + multiple converging pharmacovigilance lines (Hathaway, Grauslund, Lakhani, Cheng).

Pattern 7 — Ozempic-face / muscle-loss counseling. “I’ll lose all my muscle and look gaunt.” Patient-counseling beat: “The face changes people see are weight loss showing — same as bariatric surgery patients. Resistance training and adequate protein during weight loss preserves muscle. We can build that into your plan.”

Pattern 9 — Dysesthesia counseling. Patient on Wegovy HD 7.2 mg interpreting dysesthesia as “the drug is damaging my nerves.” Patient-counseling beat: “About 1 in 4 people on the higher dose get tingling or burning sensations. It’s not nerve damage — it’s a known side effect that resolves with dose reduction. Tell me about what you’re experiencing.” Anchored in STEP UP 22.9% dysesthesia incidence (PMID 40961952) + mechanism + reversibility.

Pattern 10 — Bench-press / squat performance counseling. “I lost strength because of semaglutide.” Patient-counseling beat: “Strength can drop during rapid weight loss for two reasons — you’re moving less mass, and if protein and lifting are off, you can lose lean tissue. The fix is protein and lifting.” Cross-reference §9.3 lean-mass-stack consideration if appropriate.

10.9 Discipline notes on engaging patient-discourse

1. Acknowledge the legitimate peer-support function of patient communities (r/Semaglutide, r/Wegovy, r/Ozempic). GI tolerability navigation, injection technique tips, NSV celebrations, taper-down peer experience provide real value. Dismissing the entire community as “misinformation” misreads the discourse landscape and damages patient trust.

2. Distinguish empirical pattern-claims from interpretive claims. “I had nausea on day 3” is empirical; “this means the drug is poison” is interpretive misreading. Clinical engagement validates the empirical observation and addresses the interpretive misreading separately.

3. “I read on Reddit” preface is itself information. Patients prefacing claims with “I read on Reddit” are signaling uncertainty and inviting clinical correction. Treat as collaborative information-evaluation moment rather than corrective monologue moment.

4. Equally engage misinformation-undercounting and misinformation-overcounting. Calibrated middle position: factual-evidence-anchored engagement that respects patient autonomy while correcting empirical errors.

11. Source citations

11.1 Purpose

Define the bibliography format, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline for this protocol. §11 is the protocol’s evidentiary spine — every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor traces to a §11 citation entry.

The full bibliography is at Primary-source citation appendix and at (~1,930 PMIDs from Phase 2 sweep + Phase 2.5 supplement). This protocol’s §11.5 carries the load-bearing-citations subset organized by tier and indication.

11.2 Bibliography format

Each citation entry contains:

• First author last name, et al. (or full author list if ≤3 authors)
• Title (exact paper title where available)
• Journal (full or standard abbreviation), Year, Volume, Pages where available
• PMID (PubMed identifier)
• DOI (if available)
• NCT (for trial reports — anchored to ClinicalTrials.gov registry)
• Effect-size summary (one-line load-bearing fact)
• Citation context (which protocol sections cite this source)

11.3 Evidence hierarchy tiers

• Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion. Examples: STEP-1, STEP-2, STEP-TEENS, STEP UP, SUSTAIN-6, SELECT, ESSENCE, FLOW, SOUL, STRIDE. These are the protocol’s effect-size and indication-scope anchors.
• Tier 1.5 — Phase 3 head-to-head RCT comparing within-class alternatives. Examples: SUSTAIN-7 (semaglutide vs dulaglutide), SURPASS-2 (tirzepatide vs semaglutide), SURMOUNT-5 (tirzepatide vs semaglutide CWM head-to-head), STEP 8 (semaglutide vs liraglutide).
• Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper, Phase 3 design publication. Supports the protocol’s mechanism rationale and dose-finding context.
• Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. Supports AE-class signals under evaluation (NAION pharmacovigilance cohort) and real-world-evidence framing.

The protocol does not invert tiers — a Tier 3 case series does not override a Tier 1 trial-program finding; a Tier 1 trial finding can be contextualized by a Tier 3 post-marketing signal but the direction-of-effect anchor remains the Tier 1 source.

11.5 Load-bearing citations subset (organized by tier and indication)

Tier 1 — pivotal Phase 3 RCT, indication-anchored.

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. PMID 33567185. NCT03548935. STEP-1; CWM-indication anchor; non-diabetic obesity; –14.9% body weight vs –2.4% placebo at 68 weeks. Cited in §1.3, §1.5, §2.2, §4.9, §5.5, §7.5, §10.2.
• Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-984. PMID 33667417. NCT03552757. STEP-2; obesity-with-T2D anchor; –9.6% weight reduction at 68 weeks. Cited in §1.3, §4.9.
• Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021;325:1403-1413. PMID 33625476. STEP-3; IBT effect-additivity; –16.0% vs –5.7% IBT-plus-placebo at 68 weeks. Cited in §1.3, §7.4.
• Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021;325:1414-1425. PMID 33755728. NCT03548987. STEP-4; maintenance-and-discontinuation anchor; post-discontinuation two-thirds weight-regain trajectory. Cited in §5.1, §7.3, §8.5, §10.7.
• Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-2091. PMID 36216945. STEP-5; two-year long-term anchor.
• Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022;327:138-150. PMID 35015037. STEP-8; semaglutide vs liraglutide head-to-head; –15.8% vs –6.4%. Cited in §1.3, §1.6, §7.4.
• Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med 2022;387:2245-2257. PMID 36322838. NCT04102189. STEP TEENS; adolescent CWM anchor; –16.1% BMI vs +0.6% placebo. Cited in §1.3, §2.2, §4.9.
• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564. PMID 35441470. STEP-1 extension; two-thirds weight regain within 52 weeks off-treatment. Cited in §7.3, §8.5, §10.7.
• Wharton S, et al. Higher-dose semaglutide 7.2 mg in obesity (STEP UP): Phase 3b randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2025. PMID 40961952. STEP UP; Wegovy HD 7.2 mg; –18.7% body weight; 31.2% achieving ≥25% loss; 22.9% dysesthesia. Cited in §1.3, §4.6, §5.2, §6.10, §7.4, §10.5.
• Lingvay I, et al. Semaglutide 7.2 mg in obesity with type 2 diabetes (STEP UP T2D). Lancet Diabetes Endocrinol 2025. PMID 40961953. STEP UP T2D; –13.2% body weight; 18.9% dysesthesia. Cited in §1.3, §6.10.
• Wharton S, et al. Oral semaglutide 25 mg in obesity (OASIS 4). N Engl J Med 2025. PMID 40934115. OASIS 4; oral Wegovy 25 mg; –13.6% TP / –16.6% adherent. Cited in §1.3, §4.9, §5.2.
• Knop FK, et al. Oral semaglutide 50 mg in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:705-719. PMID 37385278. OASIS 1; oral 50 mg obesity. Cited in canonical §4.5.
• Aroda VR, et al. Higher-dose oral semaglutide in adults with type 2 diabetes (PIONEER PLUS): a randomised, double-blind, placebo-controlled phase 3b trial. Lancet 2023;402:693-704. PMID 37385279. PIONEER PLUS; oral 25/50 mg vs 14 mg superiority. Cited in §1.3, §2.2, §5.2.
• Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844. PMID 27633186. NCT01720446. SUSTAIN-6; CV-risk-in-T2D anchor; three-point MACE HR 0.74 (26% relative MACE reduction). Cited in §1.3, §2.2, §3.6, §5.2, §6.5, §10.5.
• Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1). Lancet Diabetes Endocrinol 2017;5:251-260. PMID 28110911. SUSTAIN-1; monotherapy T2D.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. SELECT; CV-risk-in-non-diabetic-obesity anchor; three-point MACE HR 0.80 (20% relative MACE reduction) over mean 39.8 months. Cited in §1.3, §2.2, §3.6, §5.5, §10.5, §10.6.
• Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024;30:2049-2057. PMID 38740993. SELECT 4-year durability; –10.2% mean weight loss maintained at 208 weeks. Cited in §5.1, §7.3.
• McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and ASCVD/CKD (SOUL). N Engl J Med 2025. PMID 40162642. NCT03914326. SOUL; oral semaglutide 14 mg in T2D + ASCVD/CKD; 14% MACE reduction in n=9,650 — first CV outcomes trial for oral GLP-1 agent. Cited in §1.3, §2.2, §5.2, §10.5.
• Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med 2019;381:841-851. PMID 31185157. PIONEER 6; cardiovascular safety oral semaglutide in T2D.
• Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099. PMID 40305708. NCT04822181. ESSENCE; MASH F2/F3 anchor; 62.9% MASH resolution without worsening fibrosis (vs 34.3% placebo); 36.8% fibrosis improvement (vs 22.4%) at 72 weeks. FDA-approved August 15, 2025. Cited in §1.3, §2.2, §3.4, §5.5, §7.4, §10.5.
• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. FLOW; CKD-in-T2D anchor; kidney composite plus CV death HR 0.76 (24% relative reduction) at median 3.4 years; 18% lower MACE; 20% lower all-cause mortality. Cited in §1.3, §2.2, §3.5, §5.5, §10.5, §10.6.
• Bonaca MP, et al. Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE). Lancet 2025;405:1175-1186. PMID 40169145. STRIDE; T2D + symptomatic PAD; walking-capacity and quality-of-life improvement. Cited in §1.3, §2.2, §5.2.
• Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2023;389:1069-1084. PMID 37622681. NCT04788511. STEP-HFpEF; investigational-extension HFpEF anchor; KCCQ-CSS +16.6 vs +8.7. Cited in §1.3, §10.6.
• Kosiborod MN, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med 2024;390:1394-1407. PMID 38587233. STEP-HFpEF-DM. Cited in §1.3.
• Butler J, et al. Semaglutide effects on heart failure outcomes in obesity (pooled STEP-HFpEF). Lancet 2024;403:1635-1648. PMID 38599221. Pooled STEP-HFpEF; n=1,145. Cited in §1.3.
• Kosiborod MN, et al. Effects of semaglutide on heart failure outcomes across four trials (SELECT + FLOW + STEP-HFpEF + STEP-HFpEF DM). Lancet 2024;404:949-961. PMID 39222642. 4-trial pooled HF analysis; n=3,743 with HF; HR 0.69 for CV death or worsening HF events. Cited in §1.3.

Tier 1.5 — head-to-head Phase 3 RCT.

• Pratley R, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018;6:275-286. PMID 29397376. NCT02648204. SUSTAIN-7; semaglutide HbA1c reduction ~1.8 percentage points (1.0 mg) at 40 weeks; semaglutide superior to dulaglutide. Cited in §1.3, §1.6, §10.2.
• Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-515. PMID 34170647. NCT03987919. SURPASS-2; tirzepatide 15 mg HbA1c reduction ~2.3 percentage points vs semaglutide 1 mg ~1.9 percentage points at Week 40. Cited in §5.2, §7.4, §9.5, §10.5.
• Aronne LJ, et al. Tirzepatide vs Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025. PMID 40353578. SURMOUNT-5 direct head-to-head; n=751 obesity without T2D; max-tolerated-dose comparison at week 72; tirzepatide –20.2% vs semaglutide –13.7%; ~6.5 percentage-point difference favoring tirzepatide. Cited in §1.6, §7.4, §10.5.

Tier 2 — extension, mechanism, large-trial supplement, design publications.

• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015;58:7370-7380. PMID 26308095. Semaglutide medicinal chemistry foundational reference. Cited in §1.2.
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol 2019;10:155. PMID 31031702. Engineering rationale + Novo Nordisk GLP-1 RA program review. Cited in §1.2.
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756. Mechanism review.
• Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-1486. PMID 20203154. Rodent C-cell tumor signal — species-specific to rodents; basis for class-wide GLP-1 RA boxed warning despite primate non-translation. Cited in §2.4, §3.7, §6.7.
• Newsome PN, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021;384:1113-1124. PMID 33185364. NCT02970942. Phase 2 MASH anchor — precursor to ESSENCE.
• Newsome PN, et al. Design and rationale of ESSENCE Phase 3 trial of semaglutide in MASH. Aliment Pharmacol Ther 2024;60:1525-1537. PMID 39412509. ESSENCE design / baseline characteristics paper. Cited in §3.4.
• Loomba R, et al. Semaglutide in compensated nonalcoholic steatohepatitis cirrhosis: a randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2023;8:511-522. PMID 36934740. Phase 2 in F4 cirrhosis (n=71); fibrosis improvement 11% semaglutide vs 29% placebo (p=0.087, NS but directionally toward placebo advantage). Cited in §1.3, §2.3, §3.4.
• Huang Y, et al. Time-dependent profile of GI adverse events of semaglutide: a meta-analysis. J Diabetes Investig 2024. PMID 38787986. Meta-analysis; extended treatment duration (>30 weeks) associated with decreased GI event incidence. Cited in §4.3, §4.4, §6.2.
• Garvey WT, et al. Cagrilintide-Semaglutide in Obesity Without Diabetes (REDEFINE-1). N Engl J Med 2025. PMID 40544433. REDEFINE-1 Phase 3; n=3,417; –20.4% body weight (treatment-policy estimand) vs –3.0% placebo; 22.7% at full adherence vs 16.1% semaglutide alone, 11.8% cagrilintide alone. Cited in §1.6, §7.4, §9.2.
• Davies MJ, et al. Cagrilintide-Semaglutide in Obesity with Type 2 Diabetes (REDEFINE-2). N Engl J Med 2025. PMID 40544432. REDEFINE-2; n=1,206; –13.7% body weight vs –3.4% placebo; 73.5% reached HbA1c ≤6.5% vs 15.9%. Cited in §1.6, §9.2.
• Chen Y, et al. Metformin plus semaglutide in polycystic ovary syndrome: randomised controlled trial. PMID 40713699. Chen 2025 PCOS RCT; greater weight loss, testosterone reduction, natural pregnancy rate 35% vs 15% metformin alone. Cited in §1.3, §8.4, §10.4.
• Hendershot CS, et al. Semaglutide for alcohol use disorder: a Phase 2 RCT. JAMA Psychiatry 2025. PMID 39937469. Phase 2 alcohol use disorder. Cited in §1.3.
• Wang W, et al. GLP-1 receptor agonists and tobacco use disorder: target trial emulation. Ann Intern Med 2024. PMID 39074369. Target trial emulation tobacco use disorder. Cited in §1.3.
• Parker SE, et al. Pregnancy outcomes after GLP-1 RA exposure: pooled regulatory-trial review. PMID 40329607. Parker 2025; pooled review of unplanned pregnancies from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials; incidence of congenital abnormalities appears relatively low. The verbatim Anchor 3 lead citation. Cited in §1.3, §8.4, §8.7, §10.4.
• Bezin J, et al. Glucagon-like peptide-1 receptor agonists and suicide attempt or suicide: case-time-control study. EClinicalMedicine 2024;68:102403. PMID 39844933. French nationwide case-time-control; OR 0.62 (95% CI 0.51-0.75) — no signal of harm; warning removed from FDA label 2025 / EMA label 2024-2025. Cited in §2.3.

Tier 2 — comparator-class (informational for §10.5).

• Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). N Engl J Med 2023;389:514-526. Retatrutide Phase 2; ~24% body weight reduction at 48 weeks at 12 mg.
• Rosenstock J, et al. Orforglipron in Adults with Type 2 Diabetes (ACHIEVE-1). N Engl J Med 2025. PMID 40544435. Orforglipron T2D Phase 3; HbA1c absolute reduction –1.24% to –1.48% vs placebo –0.41%.
• Wharton S, et al. Orforglipron in Obesity (ATTAIN-1). N Engl J Med 2025. PMID 40960239. Orforglipron obesity Phase 3.
• Horn DB, et al. Orforglipron in obesity with type 2 diabetes (ATTAIN-2). Lancet 2026. PMID 41275875. Orforglipron obesity + T2D Phase 3.

Tier 3 — post-marketing pharmacovigilance and signals under evaluation.

• Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142:732-739. PMID 38958939. NAION-signal anchor; single-center cohort; HR 4.28 in T2D, HR 7.64 in overweight/obese. Cited in §2.3, §3.7, §6.6, §10.5.
• Grauslund J, et al. Risk of NAION with semaglutide use: Danish nationwide cohort. Int J Retina Vitreous 2024. PMID 39696569. Grauslund Danish nationwide n=424,152; HR 2.19 at 5 years. Cited in §2.3, §3.7, §6.6, §10.5.
• Lakhani DA, et al. Class-differentiated NAION signal: 180-country pharmacovigilance analysis of GLP-1 RAs. Eye 2025. PMID 40383360. Lakhani 180-country pharmacovigilance; FAERS ROR 11.12; VigiBase ROR 68.58; no significant NAION signal for tirzepatide at the same threshold — class-differentiated to semaglutide. Cited in §2.3, §3.7, §6.6, §10.5.
• Cheng C, et al. Multi-database NAION pharmacovigilance: FAERS + VigiBase confirmation. Ophthalmology 2026. PMID 41021211. Cheng 2026 confirmation. Cited in §3.7, §6.6, §10.5.
• Wen Y, et al. Pancreatitis and pancreatic cancer with GLP-1 RA: systematic review and meta-analysis of 62 RCTs. PMID 40988099. Wen 2025 SR; n=66,232; pooled RR 1.44 (95% CI 1.09–1.89, p=0.009) for acute pancreatitis — “slightly increased risk, likely minimal”; pancreatic cancer RR 1.30 (95% CI 0.86–1.97), non-significant. Cited in §2.3, §6.3.
• Ko JY, et al. GLP-1 receptor agonists and cancer outcomes: systematic review and meta-analysis of 48 RCTs. Ann Intern Med 2026. PMID 41359966. Ko 2026 definitive cancer SR; n=94,245 across 48 RCTs; moderate-certainty “little or no effect” thyroid/pancreatic/breast/kidney; low-certainty “may have little or no effect” 8 others. Cited in §2.3, §6.7.

Tier 3 — important null and contextual findings.

• Johannsen P, et al. Semaglutide in Early Alzheimer’s Disease (evoke / evoke+ Phase 3). Lancet 2026. DOI 10.1016/S0140-6736(26)00459-9. evoke / evoke+ Phase 3; n=3,808 early AD; 104 weeks; primary endpoint (CDR-SB) NOT met; hsCRP reduced but no clinical cognitive benefit. AD is not currently an evidence-supported indication. Cited in §1.3 (important null finding).

11.7 Regulatory date verification

Regulatory-status dates verified against the canonical regulatory references:

• Wegovy HD 7.2 mg FDA approval: March 19, 2026 (Commissioner’s National Priority Voucher Program; fourth NPV product; 54-day review)
• Wegovy HD EMA CHMP positive opinion: December 12, 2025
• Wegovy MASH F2/F3 FDA expansion: August 15, 2025
• Wegovy MACE non-diabetic obesity + CVD FDA expansion: March 8, 2024
• Oral Wegovy 25 mg FDA approval: August 2025
• Ozempic FDA approval: 2017
• Wegovy 2.4 mg FDA approval: 2021
• Wegovy adolescent (≥12) FDA approval: 2022
• Rybelsus FDA approval: 2019
• Rybelsus CV outcomes (SOUL-anchored) FDA expansion: 2025
• Ozempic FLOW CKD-in-T2D FDA expansion: 2025
• Ozempic CV risk reduction in T2D + CVD FDA expansion: 2020
• NAION EMA PRAC classification (“very rare”): June 2025
• NAION FDA label: US labels not updated as of 2026-05-13 (US/EU divergence)
• Suicidal ideation warning removed: FDA label 2025; EMA label 2024–2025

11.8 Full bibliography pointer

Full bibliography (~1,930 PMIDs) is at. The canonical’s Primary-source citation appendix (lines 1451–1577) provides the topic-organized load-bearing-citations subset. This protocol’s §11.5 is the protocol-scope subset of those load-bearing citations.

---

12. Clinical decision tree

12.1 Purpose

Define a phenotype-guided decision tree that integrates §§1–11 into a single navigable clinical-workflow reference. §12 is the operational summary that a clinician reaches for at point-of-care to navigate the protocol decisions: should this patient be on semaglutide, at what indication, what formulation/dose, what monitoring cadence, what are the off-ramps.

§12 is rendered as an ASCII flowchart (§12.2), a phenotype-guided decision matrix (§12.3), and four worked-example walkthroughs (§12.4–§12.7) representing common Module 5 phenotypes. The decision tree is not authority — it summarizes the authoritative content in §§1–11; if the decision tree and a §§1–11 sub-block disagree, the §§1–11 content is canonical.

12.2 High-level decision flowchart (ASCII)

 PATIENT PRESENTS
 |
 v
 [§1] Indication scope
 T2D / CWM / CV / MASH / CKD / PAD / HFpEF / adolescent / off-label? |
 v
 [§2] Selection criteria
 Inclusion criteria met? --> NO --> Out of protocol
 Relative exclusion? --> Clinician judgment
 Hard contraindication? --> YES --> Out of protocol
 (MTC / MEN-2 / hypersensitivity / pregnancy / severe pancreatitis hx)
 |
 v (Inclusion met, no contraindication)
 [§3] Pre-treatment workup
 Standard metabolic + indication-specific panels
 Organ-baseline (thyroid + pancreas + ophthalmology + NAION pre-screen)
 Body composition baseline
 |
 v
 [§4] Initiation
 Starting dose (0.25 mg SC weekly Wegovy/Ozempic; 3 mg PO Rybelsus)
 Standard 16-week titration OR slow-titration extension
 Early monitoring cadence (W2 / W5-6 / W9-12 / W17-20)
 GI tolerability management
 |
 v (Target dose attained)
 [§5] Maintenance
 Target dose held; quarterly Y1, biannual thereafter
 Indication-specific monitoring panel
 Effect-size trajectory tracked vs trial anchor (§4.9 table)
 |
 v
 [§6/§7/§8] Branch points
 AE emerges? --> §6 AE-class algorithm
 Plateau / non-response? --> §7 algorithm (5a Wegovy HD / 5b tirzepatide /
 5c CagriSema / 5d IBT intensification)
 Discontinuation trigger?

12.3 Phenotype-guided decision matrix

Phenotype dimension	Pattern	Semaglutide fit	Within-class alternatives	Cross-class additions
T2D, HbA1c 7.0–9.0	SUSTAIN-anchored	Ozempic 1.0 / 2.0 mg	Tirzepatide (SURPASS-2 higher-effect); dulaglutide; liraglutide	SGLT2 if CKD/CV; pioglitazone if MASH co-indication; metformin baseline
T2D + ASCVD/CKD oral preference	SOUL-anchored	Rybelsus 14 mg PO	Tirzepatide (no oral); other oral GLP-1 small-molecules (orforglipron pending)	SGLT2 for additive CV/kidney benefit
T2D + CVD MACE	SUSTAIN-6 anchored	Ozempic 1.0 mg	Dulaglutide REWIND; Liraglutide LEADER	SGLT2 for additive CV benefit
T2D + CKD eGFR 25–75 + UACR 100–5000	FLOW-anchored	Ozempic 1.0 mg + maximally tolerated RAS	None within-class with kidney-composite Phase 3	SGLT2 (DAPA-CKD / EMPA-KIDNEY) confirmed additive; finerenone if residual UACR
T2D + symptomatic PAD	STRIDE-anchored	Ozempic 1.0 mg	None within-class with PAD Phase 3	Standard PAD management (vascular consult, structured exercise)
CWM, non-diabetic, BMI ≥30	STEP-1 anchored	Wegovy 2.4 mg → 7.2 mg if needed	Tirzepatide SURMOUNT-1 (higher effect); CagriSema pending	M5.6 lean-mass stack if lean-mass-loss concern; IBT (STEP-3 additive)
CWM, BMI 27–30 + comorbidity	STEP-1 sub / STEP-3	Wegovy 2.4 mg	Tirzepatide SURMOUNT-1 sub-group	IBT intensification (STEP-3 effect-additive)
CWM, adolescent ≥12	STEP TEENS anchored	Wegovy 2.4 mg (adolescent label)	Liraglutide (Saxenda adolescent label)	Pediatric obesity-medicine specialist; behavioral / family intervention
CWM, oral platform preferred	OASIS 4-anchored	Oral Wegovy 25 mg PO daily	None within-class oral CWM-approved; orforglipron Phase 3 obesity pending	SNAC absorption discipline counseling required
CWM, higher-dose post-2.4 mg tolerance	STEP UP-anchored	Wegovy HD 7.2 mg	Tirzepatide 15 mg	Dysesthesia counseling (22.9% incidence); M5.6 if lean-mass concern
CV risk, non-diabetic BMI ≥27 + CVD	SELECT-anchored	Wegovy 2.4 mg	Tirzepatide CV (SURMOUNT-MMO pending)	Statins, antiplatelets standard-of-care; RAS if HTN
MASH F2/F3	ESSENCE-anchored	Wegovy 2.4 mg (MASH label)	Resmetirom (Rezdiffra, FDA-approved 2024, thyroid hormone β-agonist)	Hepatology co-management; vitamin E or pioglitazone in non-diabetic context
MASH F4 cirrhosis	NOT FOR THIS INDICATION	OUT — Loomba PMID 36934740 directionally toward placebo	Resmetirom not approved for F4; investigational survodutide (LIVERAGE-Cirrhosis)	Hepatology co-management
HFpEF + obesity	STEP-HFpEF (off-label / investigational)	Wegovy 2.4 mg off-label	None within-class approved HFpEF	SGLT2 (EMPEROR-Preserved, DELIVER) approved HFpEF; cardiology co-management
Severe gastroparesis	Relative exclusion	Caution / clinician judgment	Non-GLP-1 alternative (SGLT2, metformin)	Behavioral / surgical bariatric pathway
MTC / MEN-2 personal/family hx	Hard contraindication	OUT OF PROTOCOL — boxed warning	Non-GLP-1 alternative regardless	Per indication; behavioral / bariatric pathway
Pre-conception planning	Anchor 3 framing	Wegovy/Ozempic with ≥8-week pre-conception washout per label	Same arithmetic all GLP-1 RAs	Pre-pregnancy counseling pathway
Active pregnancy	Labeled contraindication (CWM)	Immediate discontinuation; OB co-management	Same — all GLP-1 RAs labeled-contraindicated CWM in pregnancy	Pre-pregnancy / post-pregnancy reinitiation §8.6
PCOS + fertility planning	Chen 2025 PMID 40713699	Off-label; combined metformin; 8-week pre-conception washout integrated	Same arithmetic	Reproductive-endocrine co-management
Lean-mass concern (older adult, athletic)	M5.6 stack consideration	Wegovy 2.4 mg + CJC-Ipamorelin per M5.6 v3 (off-label combination)	Tirzepatide per SURMOUNT lean-mass sub-analyses	Resistance training + protein optimization
Cost / access barrier	Anchor 1 + 2 framing	Compounded semaglutide where jurisdiction permits + FDA-approved comparison	Patient-anchored decision	Insurance-pathway counseling; patient assistance program
Prior semaglutide non-response at target dose	§7 algorithm	Wegovy HD 7.2 mg if not tried; or transition	Tirzepatide (SURMOUNT-5 / SURPASS-2 head-to-head higher effect)	IBT intensification (STEP-3 additive); CagriSema if available
Microdosing for longevity (lean / metabolically-healthy)	Anchor 5 framing	Off-label extrapolation; research-state-uncharacterized	Same — all GLP-1 RAs uncharacterized in this population	Shared-decision-making invitation; monitoring framework if proceed
Confirmed acute pancreatitis	§6.3 algorithm	Permanent discontinuation	Non-GLP-1 alternative; DPP-4 also carries pancreatitis precaution	Per indication; SGLT2 / pioglitazone alternatives
Confirmed NAION	§6.6 algorithm	Permanent discontinuation	Tirzepatide NOT class-differentiated-contraindicated (signal absent per PMID 40383360)	Patient-clinician decision per §6.6
Severe AE (anaphylaxis, severe pancreatitis, NAION)	§2.4 + §6 algorithms	Permanent discontinuation	Non-semaglutide alternatives per indication	Per indication

12.4 Worked decision-tree application — polycondition phenotype

A 49-year-old female presents with BMI 34, T2D (HbA1c 8.2), known ASCVD (prior MI 3 years ago, on statin and antiplatelet), UACR 180 mg/g (mild albuminuria), eGFR 68, no MTC / MEN-2 family history, no pancreatitis history, no gastroparesis, no active pregnancy, post-menopausal.

Decision-tree walkthrough.

Step 1 — Indication scope. Multiple indications apply: T2D (HbA1c 8.2 above target); CWM (BMI ≥27 + comorbidities); CV risk reduction (established ASCVD); CKD risk reduction in T2D (UACR ≥100, eGFR in FLOW range 25–75). Polycondition phenotype per §1.4.

Step 2 — Selection criteria. Inclusion criteria met for all four indications. No hard contraindications. No relative exclusions.

Step 3 — Pre-treatment workup. Full panel: standard metabolic (§3.2); diabetes-specific (§3.3) including HbA1c, fasting C-peptide, dilated retinal exam (HbA1c 8.2 → exam within 6 months — pre-treatment-mandated per §3.3 / §3.7); UACR documentation (already noted); CV-risk panel (§3.6) including ECG, lipid panel, hsCRP; kidney-specific panel (§3.5) including RAS-blockade documentation at maximally tolerated dose; organ-baseline (§3.7) — TSH, lipase, ophthalmology pre-screen for NAION risk; body-composition baseline (§3.8).

Step 4 — Initiation. Ozempic chosen (T2D + CV + CKD indication mix; Ozempic at 1.0 mg satisfies the polycondition mix and is the label-appropriate formulation; Wegovy is the CWM-specific formulation but Ozempic 1.0 mg is the SUSTAIN-6 / FLOW / STRIDE trial-anchored dose). Starting 0.25 mg weekly per §4.3 titration schedule; standard pace 4-week steps to 1.0 mg target by Week 13. Early monitoring per §4.5.

Step 5 — Maintenance. Target 1.0 mg weekly (FLOW dose; SUSTAIN-6 dose; SUSTAIN-7-equivalent dose). Quarterly Y1, biannual thereafter. HbA1c at Month 4, 7, 10, 13 in Y1. UACR annually. eGFR quarterly Y1, biannual thereafter. Lipid panel annually. Weight + BP at every visit.

Step 6 — Branch points. Anticipated AE profile per §6.2 — manage as standard. Non-response algorithm (§7) not anticipated at Month 6 given polycondition trial-program support; if HbA1c not at target at Month 6 on 1.0 mg, consider 2.0 mg per SUSTAIN-FORTE; if still not at target at Month 9 on 2.0 mg, consider §7 step 5b transition to tirzepatide per SURPASS-2 head-to-head.

Step 7 — Combination decisions. Patient should also be on RAS-blockade (already confirmed) and statin (already confirmed). Add SGLT2 inhibitor (empagliflozin or dapagliflozin) for additive CV and kidney benefit; standard polycondition T2D + ASCVD + CKD regimen per current ADA/EASD guidance. SGLT2 + GLP-1 RA combination well-supported (§9.2). Lean-mass stack not indicated unless lean-mass loss emerges as §5 monitoring concern.

Step 8 — Counseling beats. Initiation conversation per §10.2. Comparator conversation per §10.5 verbatim Anchor 4 — present tirzepatide as a within-class alternative with higher weight-magnitude effect-size (SURPASS-2; SURMOUNT-5), but for this polycondition patient with established FLOW / SUSTAIN-6 / SELECT semaglutide indication anchors and the NAION class-differentiation question for the patient’s ophthalmologic-risk profile, semaglutide is the trial-program-anchored choice unless tirzepatide-specific factors emerge. Pregnancy-planning conversation not applicable (post-menopausal). Compounded-vs-FDA-approved conversation per practice convention and patient cost-context (§10.3 verbatim Anchor 1 + 2).

Step 9 — Source citations. All claims above traced to §11.5: SUSTAIN-6 (PMID 27633186), SELECT (PMID 37952131), FLOW (PMID 38785209), SUSTAIN-7 (PMID 29397376), SURPASS-2 (PMID 34170647).

Step 10 — Verification gate.

The decision-tree walkthrough presents the patient’s options factually with trial-anchored effect-size estimates; the polycondition phenotype is anchored to multiple FDA-approved indications without inflating cross-indication benefit; the SGLT2 + GLP-1 RA combination is presented as standard polycondition regimen; the comparator framing presents tirzepatide as an alternative without steering; the off-label / extrapolation transparency is not triggered (all uses are label-supported for this patient).

12.5 Worked decision-tree application — non-diabetic CWM with non-response

A 52-year-old female, non-diabetic, BMI 33 (baseline), prior weight-loss attempts including 18 months on phentermine with regain. Initial Wegovy 2.4 mg titration completed by Week 17; at Month 6 on target dose: 3.2 kg lost (~3% of starting weight). No GI AE breakthrough; adherence confirmed.

Decision-tree walkthrough.

Steps 1–4 per §4.9: STEP-1 anchored phenotype; Wegovy 2.4 mg initiation appropriate; on-protocol.

Step 5 — §7 non-response algorithm. Adherence confirmed; trajectory below STEP-1 25th percentile (~7% at Month 6); on target dose; phenotype trial-enrolled. Non-response confirmed.

Decision branches presented (§7 step 5). (5a) Wegovy HD 7.2 mg escalation per STEP UP — patient has tolerated 2.4 mg ≥4 weeks, label-permitted; dysesthesia counseling per §6.10. (5b) Transition to tirzepatide per SURMOUNT-5 / SURPASS-2 higher-effect data. (5c) CagriSema if available per local regulatory status. (5d) IBT intensification per STEP-3 effect-additivity.

Step 6 — Counseling beats. Verbatim Anchor 4 multi-dimensional comparator framing. Patient is informed of weight-magnitude differential (tirzepatide head-to-head higher), of NAION class-differentiation (semaglutide signal documented; tirzepatide absent), of GI tolerability similarity, of cost / access. Patient-anchored decision. If patient chooses Wegovy HD 7.2 mg, dysesthesia counseling per §10.8 Pattern 9 (“It’s not nerve damage — it’s a known side effect that resolves with dose reduction”). If patient chooses tirzepatide transition, §8 abrupt discontinuation acceptable given immediate same-class replacement; tirzepatide protocol initiation.

12.6 Worked decision-tree application — ESSENCE-anchored MASH F3 patient

A 51-year-old female with biopsy-confirmed MASH F3 fibrosis, BMI 34, no T2D, no other major comorbidities. AST 84 / ALT 92; FIB-4 3.1; FibroScan 12.4 kPa pre-treatment.

Decision-tree walkthrough.

Step 1 — Indication scope. MASH F2/F3 per ESSENCE label (Wegovy 2.4 mg, FDA-approved August 2025).

Step 2 — Selection criteria. Inclusion criteria met. No contraindications.

Step 3 — Pre-treatment workup. Standard metabolic + full MASH-specific panel (§3.4) — AST/ALT/GGT/platelet count/FIB-4/VCTE (already pre-treatment); viral hepatitis screen (HBsAg / HCV Ab) negative; iron studies normal; autoimmune liver-disease screen not clinically indicated. Hepatology co-management initiated for F3 fibrosis. Organ-baseline (§3.7) — TSH, lipase, ophthalmology pre-screen.

Step 4 — Initiation. Wegovy 0.25 mg → 2.4 mg standard titration. Slow-titration option offered given patient request for conservative pace.

Step 5 — Maintenance. Target Wegovy 2.4 mg. Quarterly visits Y1 with weight + BP + body composition; biannual LFT + FibroScan with hepatology co-management. Re-biopsy or imaging confirmation per hepatology recommendation at ~72 weeks per ESSENCE primary-endpoint timeline if clinically indicated.

Step 6–8. Anticipated AE profile manage per §6. Comparator counseling per §10.5 — Resmetirom (Rezdiffra) is the alternative-class FDA-approved MASH therapy (thyroid hormone β-agonist; March 2024 approval); patient-clinician decision per multi-dimensional framing (mechanism, AE profile, cost, monitoring complexity). Hepatology co-management ongoing.

Step 9. All claims traced to ESSENCE (PMID 40305708), Loomba 2023 F4 caveat (PMID 36934740 — F4 cirrhosis exclusion documented).

12.7 Worked decision-tree application — adolescent ≥12 STEP TEENS-anchored CWM

A 14-year-old female, BMI at the 97th percentile (~33 kg/m² for age and sex), polycystic ovary syndrome symptoms emerging, prior dietary intervention unsuccessful. Family-history: maternal T2D; no MTC / MEN-2.

Decision-tree walkthrough.

Step 1 — Indication scope. Adolescent CWM ≥12 per STEP TEENS (PMID 36322838); Wegovy adolescent label.

Step 2 — Selection criteria. Inclusion criteria met (BMI 95th+ percentile). No hard contraindications. Relative consideration: post-menarcheal female — contraception counseling per §6.11 oral contraceptive absorption considerations critical.

Step 3 — Pre-treatment workup. Standard metabolic + diabetes-specific (HbA1c, fasting glucose, fasting C-peptide; pre-diabetes screen given family history). Organ-baseline (§3.7). Body-composition baseline (§3.8). Growth and developmental baseline. Psychosocial baseline. Pediatric obesity-medicine specialist co-management initiated.

Step 4 — Initiation. Wegovy 0.25 mg → 2.4 mg standard adolescent titration (mirrors adult). Slow-titration option emphasized given adolescent GI tolerability and adherence considerations. Patient-and-parent / guardian counseling on indefinite-treatment expectation.

Step 5 — Maintenance. Target Wegovy 2.4 mg. Quarterly visits with pediatric obesity-medicine specialist. Growth, development, psychosocial surveillance. PCOS context (Chen 2025 evidence base) — pre-treatment counseling on potential fertility implications.

Step 6–8. Anticipated AE profile manage per §6. Pregnancy-planning counseling integrated at age-appropriate level with parent / guardian and patient — verbatim Anchor 3 framing. Comparator counseling: liraglutide (Saxenda adolescent label) is the within-class alternative; STEP-8 head-to-head data (PMID 35015037, adult) suggests semaglutide ~2.5× greater weight reduction.

Step 9. All claims traced to STEP TEENS (PMID 36322838) and STEP-8 (PMID 35015037).